Blog | Roots Analysis

March 17, 2023

mRNA Therapeutics and mRNA Vaccines Industry: Current Scenario and Future Trends

By Jasmeet Bhalla mRNA 0 Comments

Messenger ribonucleic acid (mRNA) is a single-stranded molecule that is complementary to a gene’s DNA. It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein. In the last few years, researchers have become interested in

March 16, 2023

Novel Cell Cytometers: Need of the Hour

By Yash Kumar Cell Cytometers 0 Comments

The domain of novel cell cytometers has attracted much attention of within the global biopharmaceutical industry in recent years. This popularity can be attributed mainly to the need of these tools to address the rising prevalence of chronic disease conditions. Cell cytometers allow for the simultaneous characterization of cells from a mixed population, thereby helping

March 15, 2023

Patient Recruitment – Key Determinant of Successful Clinical Trials

By Simran Kaur Patient Recruitment 0 Comments

Clinical trials are a fundamental requirement for evaluating the safety and efficacy of novel therapeutic interventions. Initiating a clinical trial is a complex and time-consuming process, involving suitable planning and execution. In addition, there are several other challenges, including inefficiencies related to data handling, and difficulties associated with patient enrollment and retainment, which further complicates

March 14, 2023

Exploring AI-based Digital Pathology

By Ronit Sharma Diagnostics, Digital Therapeutics, Non-Invasive Diagnostics 0 Comments

How is AI being used in Digital Pathology? Digital pathology is a transformative technology that has enabled pathologists to make the shift from visual inspection of tissue samples to automated image analysis. With the advent of AI, pathologists are now benefiting from computerized image analysis software that can draw conclusions and deliver diagnoses in a

March 10, 2023

Rare Kidney Disorders: Future Miracle Drugs

By Sayoni Banerjee Chronic Kidney Disease 0 Comments

Kidney disorders are one of the most common causes of mortality, accounting for 850 million deaths, per year, across the globe. Over 300 congenital, inherited and acquired disorders fall under the umbrella of rare kidney disorders. It is worth mentioning that these set of disorders are known to have a serious effect on the general

March 9, 2023

Smart pharmaceutical and healthcare labels: Lets trace medicines from its origin

By Simriti Gupta Anti-Counterfeiting 0 Comments

Traditionally, text and images were printed on pharmaceutical products to convey important information. In recent years, the use of smart labels allows the developer to convey a greater amount of information about the product to the consumers, without the need for additional packaging space. It is worth noting that smart labels contain a transponder code

March 8, 2023

Introduction To Exosome Therapeutics

By Aanchal Chaudhary Exosomes, NOVEL DRUG 0 Comments

T-Cell Immunotherapies- A New Paradigm in Cancer Treatment

In recent years, therapies utilizing extracellular vesicles have garnered significant attention among the industry stakeholders for the treatment of diverse target indication, primarily owing to the various benefits offered by them, including target specificity, enhanced tissue regeneration, and reduced inflammation and chronic pain. Over time, various research studies have demonstrated the potential of exosomes (membrane

March 7, 2023

Unlocking the Potential of Digital Twins in Healthcare: Benefits, Challenges and Opportunities

By Gaurav Raj Digital Therapeutics 0 Comments

Rising Demand for Medical Devices Contract Research Service Providers

The application of digital twins in healthcare has the potential to revolutionize patient care, improve clinical outcomes, and reduce costs. Digital twins, or virtual replicas of physical objects and environments, are being used in many different industries, and healthcare is no exception. In healthcare, these can be used to provide better patient monitoring, improve remote

March 3, 2023

Investment Opportunities in Women’s Digital Health

By Diksha Agarwal Digital Therapeutics, Women’s Digital Health 0 Comments

Digital health is a broad term that refers to the utilization of communication and information technologies to manage, track, and improve the overall healthcare delivery system. Owing to the potential of digital technology to optimize patient healthcare and the development of pharmaceuticals, the digital healthcare industry has witnessed significant rise in investments in the past

March 2, 2023

Genotoxicity Testing: Unlocking the Future Safety Assessment Opportunities

By Pomila Kaushal Testing Services 0 Comments

CAR-T Cell Therapies: Advancing Immune Cells to Treat Cancer

Genotoxicity testing refers to the evaluation of detrimental effects of chemical or physical agents on the genetic processes and related hereditary material of living cells. On the other hand, mutagenicity is the process of inducing irreversible and transmissible alterations in the genetic material of organisms either spontaneously or through mutagenic activity. Disruption of the integrity

March 1, 2023

Adeno-Associated Viral Vectors: Unlocking the Future Opportunities

By Pomila Kaushal Delivery Systems, Gene Therapy, Vector Manufacturing 0 Comments

Given the potential of gene therapies in targeting the underlying cause of a disease at cellular level, the demand for such therapies has increased considerably over the past few years. Currently, more than 285 gene therapies are being evaluated in different phases of clinical development. Further, various gene therapy developers have raised more than USD 10 billion

February 28, 2023

Modular Construction – Retrofitting Conventional Buildings

By Nishta Garg MODULAR FACILITIES 0 Comments

Shifting construction away from traditional sites and into factories could dramatically change the way we build. Will off-site builds bolster construction this time around? Over the years, construction has straggled behind other sectors in terms of efficiency. Off-site builds or modular construction is a powerful way to reform construction business saving more time, labor, cost

February 27, 2023

Long-Acting Drug Delivery: A Novel Pharmacological Strategy to Deliver Therapeutic Modalities

By Prachi Bhalla Drug Delivery, Injectors, Injectors Market, Medical Devices and Technology 0 Comments

Over the last two decades, the pharmaceutical industry has observed a paradigm shift from conventional drug delivery strategies to the long-acting drug delivery (LADD) of products to treat several disease indications, such as ophthalmic disorders, oncological disorders, neurological disorders and infectious diseases. LADD has emerged as the novel and advanced drug delivery system which manipulate

February 24, 2023

Digital Therapies: The “Digital Pills” of current generation

By Sourindra_Laha Digital Therapeutics, Women’s Digital Health 0 Comments

Exploring How Artificial Intelligence Is Transforming Digital Pathology

As per United Nation’s report, the current global population stands at around 8 billion and expected to reach 9 billion by the end of 2030. This increase in population is accompanied with a rise in the incidence of several chronic disease indications. In fact, as per a report published by National Association of Chronic Disease

February 23, 2023

Medical Device Coatings and Modification Technologies

By Kumar Shagnick Medical Device, Medical Device Coatings, Medical Devices and Technology 0 Comments

Over the past 50 years, the medical device industry has seen several notable developments. In fact, according to the World Health Organization (WHO), presently, around two million medical devices are available across the globe. Further, since 2020, the Food and Drug Administration (FDA) has approved 125 medical devices. The growing demand for complex medical devices,

February 17, 2023

Demand for Outsourcing Biologics Fill Finish Services

By Ridhima Gupta Biologics 0 Comments

Th increasing demand for biologics has led to an increasing need for production capacity, which is characterized by high quality standards. Although, it is a challenging field, outsourcing has emerged as a promising segment, especially for drug product manufacturing and aseptic fill / finish operations. Despite being one of the crucial steps of all the

February 16, 2023

The Future of Dentistry: Dental 3D Printing

By Rohit Pareek 3D Bioprinting, Dental 3D Printing 0 Comments

3D printing, also known as additive manufacturing, is a method of producing 3-dimensional objects layer-by-layer, using a computer aided design. Owing to its ability to print complex models using a wide range of materials, 3D printing has applications across various industries, including dental, aerospace, automotive, healthcare, food, fashion, mechanical engineering and other manufacturing industries. In

February 15, 2023

Bioavailability Enhancement Technologies

By Jayita Sood Service Providers 0 Comments

A study conducted on terminated drug development projects revealed that majority of the drug candidates fail in early drug development phases, due to the problems associated with their pharmacokinetic profiles, ADME (distribution, metabolism, absorption and excretion) properties and toxicity-related issues. Moreover, it is a well-established fact that the systemic / local absorption and distribution of

February 14, 2023

Liposomes Development: Service Providers Landscape

By Diksha Agarwal lipososomes, Service Providers 0 Comments

Advancements In Automation Of Manufacturing Processes- Key Value Driver For Escalated Interest In The Cell Therapy Domain

In recent years, liposomes have garnered significant interest of researchers, as well as industry players, owing to their potential in diagnosis and treatment of various diseases, with a focus on delivering drugs and genetic material. Liposomes are small, artificial and lipid-based bilayered spherical vesicles, which are created spontaneously by hydrated phospholipids. Owing to their ability

February 13, 2023

mRNA Synthesis: ManufacturingProcess of Modern Revolutionary Molecule

By Ajay Kumar mRNA 0 Comments

Messenger ribonucleic acid (mRNA) is a single-stranded molecule, which carries coding sequence and plays a prominent role in protein synthesis. It transfers genetic information form to DNA to ribosomes, a specialized structure, or organelle, which decodes genetic information into a protein. Structure of mRNA Post the onset of the COVID-19 pandemic mRNA has emerged as

February 10, 2023

TIL Therapies: A New Paradigm in Cancer Treatment

By Ajay Kumar Cancer, cancer therapeutics, T-Cell Immunotherapies, T-Cell Therapies 0 Comments

Modified tumor-infiltrating lymphocytes or TIL therapies have emerged as a viable and potent option to selectively eradicate the tumor population, with minimal side effects. Till date, several clinical trials have demonstrated the efficacy and therapeutic superiority (over conventional treatment options) of TIL-based therapies. Their tumor-cell killing efficiency is attributed to the fact that they are

February 9, 2023

Viral Clearance and Viral Testing Services

By Manoti Vyas Testing Services 0 Comments

Considering the rising demand for biologics, innovators in the biopharmaceutical industry are constantly exploring avenues that would enable them to overcome the existing technical and operational challenges related to viral-clearance and testing for timely approval of biologics. Outsourcing the viral-clearance and viral testing studies has emerged as a promising alternative for most of the manufacturers.

February 8, 2023

Artificial Intelligence (AI) In Oncology: Current Scenario And Future Potential

By Muskaan Arora artificial intelligence, Cancer, CANCER MARKET, cancer therapeutics, Novel Cancer, Oncology 0 Comments

Artificial Intelligence In Oncology: Current Scenario And Future Potential

In the last decade, the popularity of AI has grown invariably. Specifically, it has made a considerable impact in the medical sector and oncologic treatment as well, due to a surge in electronic data, breakthroughs in technological infrastructure and groundbreaking research in deep learning neural networks. AI has demonstrated potential in improving tumor imaging diagnosis

February 7, 2023

Rising Demand for Medical Devices CROs

By Simriti Gupta Medical Device, Medical Devices and Technology 0 Comments

Over the past decade, numerous scientific and technological breakthroughs in the medical device CROs industry have resulted in an accelerated pace of research and innovation within this domain. Further, the demand for advanced and minimally invasive medical devices has been augmented due to the increase in expenditure on healthcare. However, one of the primary challenges

February 6, 2023

SARM1 Inhibitors: A Novel Approach Against Neurodegenerative Disorders

By Rohit Pareek Alzheimer's Disease, Alzheimer's Pipeline, Alzheimer’s Disease, Neurodegeneration, Parkinson’s Disease 0 Comments

Presently, several industry and non-industry stakeholders are evaluating SARM1 inhibitors as potential therapeutic agents for the treatment of neurological disorders across various preclinical studies and early stages of clinical development, worldwide. Given the encouraging research outcomes, the players in this domain have received more than USD 10 million in grants, since 2014, from the various

February 6, 2023

TCR Therapies: An Emerging Therapeutic Modality

By Ajay Kumar T-Cell Therapies, TCR therapies 0 Comments

Modified T-cell receptors or TCR therapies is an emerging class of adoptive therapy that employs genetically modified lymphocytes to target specific tumor markers. Structurally, TCR is a heterodimer comprising of two different polypeptide chains, namely the α-chain and β-chain. TCR therapies’ tumor-cell killing efficacy may be primarily attributed to the fact that they are pre-sensitized

February 3, 2023

Cell Therapy – The Revolutionary Therapeutic Modality: All Set To Obliterate Oncological Disorders

By Dhriti Gulati Cell Therapies, Cell Therapy, Manufacturing, Stem Cell Therapy, Stem Cells, T-Cell Immunotherapies, T-Cell Therapies 0 Comments

The American Society of Gene and Cell Therapy (ASGCT) defines cell therapy as a therapeutic modality that involves the administration of either normal or modified cells to patients for the treatment of various diseases. In this form of therapy, patients are injected with living and intact human cells that are deemed to be capable of

February 2, 2023

4D Bioprinting Market: Key Trends

By Shreeya Agrawal 3D Bioprinting, 4D Bioprinting 0 Comments

THE REVOLUTIONARY THERAPEUTIC MODALITY – CELL THERAPY: ALL SET TO OBLITERATE ONCOLOGICAL DISORDERS

What is 4D Bioprinting? 4D bioprinting refers to the addition of a fourth dimension that enables 3D printed structures to change their shape with time with the help of smart biomaterials, which have the tendency to morph in the presence of stimuli (such as, heat, water, light, electricity, magnetic energy, stress, strain, and pressure). Various

February 1, 2023

Applications of Blockchain in Various Sectors: An Introduction

By Muskaan Arora Blockchain, Clinical Trials, Cybersecurity, Healthcare, virtual clinical trials 0 Comments

Introduction and Applications of Blockchain The term blockchain refers to the way it stores transaction data in blocks that are linked to form a chain. Since every entry is stored as a block on the chain, the length of the chain increases as more transactions are recorded and stored. The digital ledger technology was developed

January 31, 2023

Intracellular Drug Delivery – Future Potential

By Tanya Shastri CELL TARGETING, Drug Delivery, Targeting Therapies 0 Comments

Healthcare treatment is important for those having fatal diseases and so is the precision treatment in almost every case. One of such disease which has squabbled the entire humanity and accounts for the highest number of death rates globally is cancer. It’s a disease wherein the body’s abnormal cells grow uncontrollably and spread to other

January 30, 2023

T-cell Immunotherapies: The Future of Modern Cancer Treatments

By Ajay Kumar Cell Therapies, T-Cell Immunotherapies, T-Cell Therapies 0 Comments

Cancer is known to be one of the leading causes of deaths worldwide. In fact, as per the WHO, close to 10 million cancer related deaths were reported in 2020. Further, it is estimated that, by the end of 2040, 27.5 million new cancer cases will be added to the global numbers, exerting tremendous physical,

January 23, 2023

Monkeypox: Disease Overview, Transmission and Diagnosis

By Divya Nagla Viral Diseases 0 Comments

Monkeypox is a viral disease, which is usually transmitted to humans from animals. The disease is known to have symptoms similar to those observed in smallpox patients, although it is considered to be clinically less severe. In recent years, monkey pox has emerged as a prominent orthopox virus affecting public health. In May 2022, multiple

January 18, 2023

Antiviral Drugs Development: Are we Prepared for the Next Viral Pandemic?

By Rohit Pareek COVID-19, COVID-19 Pandemic, Covid19, NOVEL DRUG 0 Comments

Infectious diseases are known to be one of the top 10 leading causes of deaths, worldwide. In-fact, more than 40 million people are affected by various types of infectious diseases annually. Further, it has been around three years since the COVID-19 pandemic hit the world, and yet, shows no signs of disappearing. An article published

January 17, 2023

Exploring How Artificial Intelligence Is Transforming Digital Pathology

By Ronit Sharma artificial intelligence, Diagnostics, Non-Invasive Diagnostics 0 Comments

How is AI being used in Digital Pathology? Digital pathology is a transformative technology that has enabled pathologists to make the shift from visual inspection of tissue samples to automated image analysis. With the advent of AI, pathologists are now benefiting from computerized image analysis software that can draw conclusions and deliver diagnoses in a

January 16, 2023

At-home Self-testing: A Giant Leap Towards Transformation in Diagnostic Sector

By Simriti Gupta At-home Self-testing, Diagnostics, Non-Invasive Diagnostics 0 Comments

In the health industry, digitization has evolved over time with numerous advances to ensure that everyone has equitable access to health products and medical specialists. At-home Self-testing has the ability to improve health equity and accelerate progress toward universal health coverage, and it has the capacity to alter health care. Self-testing alternatives provide individuals and

January 13, 2023

SARM1: A Potential Therapeutic Target For Neurodegenerative Diseases

By Rohit Pareek Neurodegeneration 0 Comments

Neurological disorders are considered the second leading cause of death and the primary cause of long-term disability, worldwide. In fact, over 6.5 million neurological disorder related deaths are reported annually, globally. Further, according to a report published by the United Nation (UN), close to 1 billion people, across the globe, suffer from various types of

January 12, 2023

Advancements in Automation of Processes: Key Value Driver for Escalated Interest in Cell Therapies Manufacturing Domain

By Dhriti Gulati Cell Therapies, Cell Therapy, Contract Manufacturing 0 Comments

Considering the vast potential of cell therapies in the treatment of rare disorders and sufficient body of evidence validating the clinical benefits / therapeutic potential of this complex class of biologic drugs, cell therapies have garnered considerable attention of players engaged in the healthcare industry, in the past few years. The focus of stakeholders has

January 11, 2023

CAR-T Cell Therapies: Addressing Key Unmet Needs Across Various Oncological Indications

By Ajay Kumar Cell Therapies, Cell Therapy, T-Cell Therapies 0 Comments

Amidst the active initiatives undertaken to develop more targeted anti-cancer therapies, CAR-T therapies have emerged as a promising option, given their ability to eradicate tumor cells from the body with minimal treatment-related side effects. Further, CAR-T cell therapies, relatively recent addition to the gamut of anticancer interventions, has demonstrated significant promise. Overall, this highly specific

December 13, 2022

Rising Need of Organ on a Chip Products And Technologies

By Simriti Gupta 3D Bioprinting, Healthcare 0 Comments

RISING NEED OF ORGAN-ON-CHIP PRODUCTS AND TECHNOLOGIES

The process of drug development and safety testing is extremely expensive and time-consuming. Animal testing is a vital part of drug development process, which is beneficial for researchers in understanding the cause, diagnosis, and treatment of various medical conditions. However, there are several concerns over the validity of animal research; drugs that seem to be

December 12, 2022

T-Cell Immunotherapies Market: A New Paradigm in Cancer Treatment

By Ajay Kumar T-Cell Immunotherapies, T-Cell Therapies 0 Comments

Cancer is one of the leading causes of mortality, accounting for 0.6 million deaths in 2021, in the US alone. As per the International Agency for Research on Cancer (IARC), by 2040, there are likely to be 27.5 million new cases and 16.3 million deaths related to cancer, annually. Although cancer therapeutics continue to be

December 12, 2022

Antibody Drug Conjugates Market: The Future of Novel Therapies

By Bhavishya Bhardwaj ADC Conjugation, ADC Cytotoxic Payloads, ADC Therapeutics, ADCs Pipeline 0 Comments

ANTIBODY DRUG CONJUGATES- THE FUTURE OF NOVEL THERAPEUTICS

Antibody drug conjugates (ADCs) are an upcoming class of targeted therapeutic agents that have garnered the attention of pharmaceutical companies, and academic / research institutions across the world. Fundamentally, these complex biotherapeutic entities represent the combination of the target specificity of an antibody and the therapeutic features of a chemotherapy / cytotoxic drug. Such conjugates

December 12, 2022

CAR-T Cell Therapies: Advancing Immune Cells to Treat Cancer

By Ajay Kumar Cell Therapies, T-Cell Therapies, Therapies 0 Comments

Cancer is known to be one of the leading causes of deaths worldwide. In fact, as per the WHO, close to 10 million cancer related deaths were reported in 2020. Further, it is estimated that, by the end of 2040, 27.5 million new cancer cases will be added to the global numbers, exerting tremendous physical,

August 29, 2022

Spatial Genomics, Transcriptomics and Proteomics Solutions – An Amelioration of Tissue Analytics

By Nishta Garg Genomics, SPATIAL GENOMICS 0 Comments

Recent advances in multi-omics approaches, including genomics, transcriptomics, proteomics, metabolomics, cytometry and imaging, in combination with bioinformatics and biostatistics, have been translated into several popular bioanalytical platforms, such as next-generation sequencing (NGS), single-cell analysis, flow cytometry and mass spectrometry. These platforms, although widely adopted, require tissue fixation and are therefore not capable of providing fundamental

June 2, 2022

DNA Cloning Market: A Step Towards Future of Genetics Science

By Tamanna Sharma DNA Cloning Market 0 Comments

Over the past decade, the field of synthetic biology has witnessed several advancements. DNA cloning is the field of synthetic biology which can be helpful to understand the effect of mutation on a particular gene. Many diseases that can be treated using DNA cloning, such as leukemia and sickle cell anemia, involving the replacement of

May 12, 2022

Targeted Protein Degradation Market: Riding on the Popularity of PROTAC, Market is set to Grow Exponentially

By Gaurav Chaudhary Degradation Market 2 Comments

Targeted Protein Degradation Market Report

Over the years, the drug hunters have tried to target the tens of thousands of proteins responsible for sickness and health. But a vast majority of them have remained out of reach. While, the scientific evolution has led to the development of potent and selective small-molecule inhibitors of protein function, but still, multiple targets of

May 3, 2022

Is Blue Ocean Strategy The Silver Bullet For Emerging Teleradiology Players to Achieve A Breakthrough In This Highly Competitive Market?

By Gaurav Raj Teleradiology Services Market 0 Comments

Blue ocean strategy, a concept first introduced in 2004, by W Chan Kim, and Renee Mauborgne in their bestselling book of the same name, talks about how to achieve a breakthrough in a highly saturated market by focusing on creating a new uncontested market. Blue ocean strategy is a systematic approach that helps emerging service

May 2, 2022

Plant Host Systems: A Novel Advancement in Protein Expression

By Yuveena Singh Plant Host Systems 0 Comments

In the past few years, plants have been gaining a rapid traction, involving genetic modification and expression of new genes in plant host cells. Owing to significant advantages over conventional expression systems, such as low production costs, product safety, and ease of scaling up, plants are being widely recognized as a potential platform for the

April 26, 2022

Women’s Digital Health: A New Era of Female Healthcare

By Arun Gupta Women’s Digital Health 0 Comments

Women’s digital health involves the initiatives taken by industry stakeholders and researchers, which include technological remedies, such as mobile apps, software, wearable devices and diagnostic tools that exclusively aid in improving female health and wellness. Since it is primarily focused on women’s healthcare, it is termed as Female Technology or FemTech. The term “FemTech” was

April 22, 2022

Sustainable, biodegradable and Eco- Friendly Packaging: A Paradigm Shift in Healthcare Packaging

By Nobel Dhingra Healthcare Packaging 0 Comments

What is Sustainability and Why is Sustainability Important? The term sustainability is derived from the Latin word sustinere, which means to hold or support. Sustainable packaging is defined as packaging that is safe for individuals, as well as the environment, while meeting all requirements for performance, cost and ease of fabrication. Further, the product should be specially

April 20, 2022

Rising Demand for Pharmaceutical Secondary Packaging Providers

By Rohit Pareek Pharmaceutical Secondary Packaging 0 Comments

On an average, around 50 drugs are approved by the US Food and Drug Administration (US FDA) annually. Further, studies indicate that more than 100,000 tons of pharmaceutical products are consumed globally per year. In addition, over the next five years, the global pharmaceutical market is projected to grow at a CAGR of 4.7%, with

April 19, 2022

Single-use Technology: A Step Towards Future Transformation

By Rupali Bhardwaj Single-use Technology 0 Comments

Over the past decade, the biopharmaceutical industry has witnessed several advancements in terms of bioprocessing. Bioprocess technology is one of the integral parts of biotechnology that deals with different biological processes involving living or competent cells to get value added products at the end of the process. Recently, an increasing demand for various efficient technology

March 28, 2022

Continuous Manufacturing: A Magic Bullet to Meet the Demand for Pharmaceutical Products

By Tanya Shastri Continuous Manufacturing 0 Comments

Over the last few decades, the pharmaceutical industry has been using batch processes for production of pharmaceutical products, which is a multi-phase process. However, the surge in the demand for drugs due to COVID-19 has led the pharmaceutical industry to shift on to a more agile and flexible technique- continuous, which is a single flow

March 25, 2022

Metabolomics: An Emerging yet Powerful Tool in Clinical Research and Development

By Jayita Sood Metabolomics 0 Comments

Scientific fields involved in high throughput measurement of biological molecules are referred with the suffix-omics including, transcriptomics, genomics, proteomics and metabolomics. Genomics is the study of genetic material within a cell, and transcriptomics is the study of gene activity in different cells. Likewise, metabolomics refers to the study of byproducts of metabolism. Although, metabolomics is

March 22, 2022

Subcutaneous Biologics: The Unmet Requirement in the Pharmaceutical Space

By Ronit Sharma Biologics 0 Comments

Over the years, the incidence and prevalence of chronic diseases, have increased significantly. Presently, the recommended treatment options for such clinical conditions are mostly biologics, which need to be administered via parenteral routes to ensure maximum therapeutic benefit. Given the inherent requirement for frequent medication, patients suffering from such long-lasting clinical conditions generally end up

March 16, 2022

Exosomes: A Deeper Look into Service Providers Market

By Aanchal Chaudhary Exosomes 0 Comments

Over the years, applications of exosomes in therapeutics have undergone an evolutionary change, in terms of cost of research, technology used, and duration of the study. Moreover, various startups and small firms have entered into collaborations in order to advance their innovations and offer specialized research expertise, services and technologies. In order to promote the

March 14, 2022

Biopharmaceutical Excipient Manufacturing – Current Scenario and Future Trends

By Arun Gupta Biopharmaceutical 0 Comments

Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. In fact, over 8,000 biological pharmaceutical products are currently

March 11, 2022

Exosomes: A Trending Term in Therapeutic Domain

By Aanchal Chaudhary Exosomes 0 Comments

Exosomes have been of great interest in the recent years due to the discovery of their potential in so many research and analytic procedures. Exosomes are known to have some unique functions, such as their ability to alter recipient cell bioactivities, acting like intercellular messengers and also having therapeutic potential in disease diagnostics as well

March 10, 2022

Biopharmaceutical Excipient Manufacturing Market: Current Scenario and Future Potential

By Pemba Lahmo Biopharmaceutical 0 Comments

Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines, and gene therapies), by the US FDA, have steadily risen. In fact, over 8,000 biological pharmaceutical products are currently

March 7, 2022

Complement Therapeutics: The Clinical Antidote for Complement-Associated Diseases

By Diksha Agarwal Complement Therapeutics 0 Comments

Complement System: Key Component of Immune System Complement system was discovered in 19th century as a part of immune system responsible for tissue repair and homeostasis, thereby providing first line of defense against multiple infections. This complete process is in association with a complex and highly regulated assembly of proteins which involve several soluble and

March 4, 2022

Next Generation Complement Therapeutics: Potential Life-Changing Therapies for Multiple Rare Disorders

By Diksha Agarwal Complement Therapeutics 0 Comments

Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications. Some of the complement therapeutics, namely Berinert®, Cinryze®, ORLADEYO®, Ruconest® and TAKHZYRO® were approved for the treatment

March 3, 2022

Oral Protein / Peptide-based Drugs: Addressing Key Unmet Needs Across Disease Indications

By Simriti Gupta Oral Protein 0 Comments

Orally administrable protein / peptide-based therapeutics offer several advantages including, effective treatment of numerous clinical conditions and degenerative disorders. Interestingly, recent advances in this domain have led to the development of several treatment strategies that, according to developers, exhibit the necessary capabilities to overcome challenges posed by traditional oral protein formulations and peptide-based therapies. One of

March 2, 2022

Intranasal Therapeutics and Drug Delivery Systems: The Perfect Alternative to Conventional Route of Administration

By Bhavishya Bhardwaj Intranasal Therapeutics 0 Comments

The intranasal route of administration is widely accepted as effective and non-invasive option for the local and systemic delivery of several types of active pharmaceutical ingredients (API). Majority of such formulations are designed to treat chronic obstructive pulmonary disorders (COPD), asthma and other respiratory diseases. Interestingly, over the past few years, drug developers focused on

February 28, 2022

Container Closure Integrity Testing: A Necessity for Pharmaceutical Industry

By Ridhima Gupta integrity testing 0 Comments

Over the past few years, the pharmaceutical industry is growing a tremendous pace. Considering patient’s health and safety, the drug products are expected to be free from microbial contamination and should be safe for use throughout the drug’s life cycle. Therefore, several quality checks are performed to ensure product’s sterility and stability. One of the

February 25, 2022

Accelerating Oligonucleotide Demand: A Force Driving The Contract Manufacturing Market

By Dhriti Gulati Oligonucleotides 0 Comments

Since the approval of the first antisense therapy in 1998, oligonucleotides have been in light for their capabilities as therapeutic agents. Oligonucleotides are short synthetic nucleotide chains with immense potential in the diagnosis and treatment of a myriad of disease indications. In addition to therapeutics, these complex molecules act as a significant resource in various

February 24, 2022

Next Generation Sequencing (NGS) Library Preparation Kits: Revolutionizing the Field of Genetic Sciences

By Arun Gupta Next Generation Sequencing 0 Comments

NGS has emerged as an evolutionary technology in modern biotechnology and healthcare research, enabling researchers to develop a better understanding of the cause and consequences of disease. Over the past few years, several companies have started offering a diverse range of genome sequencing products and services using various second and third generation sequencing technologies. Presently,

February 23, 2022

Rising Need of Autoinjectors

By Ishita Nanda Autoinjectors 0 Comments

With the increasing global population, the incidence rates of several chronic disease indications, such as diabetes, anaphylaxis, rheumatoid arthritis and psoriasis, are on the rise. This has led to a rise in the demand for effective treatment options for patients suffering from these diseases. Further, in order to improve the quality of life in these

February 22, 2022

Next Generation Sequencing (NGS) Library Preparation Kits Market: Current Scenario and Future Potential

By Arun Gupta Next Generation Sequencing 0 Comments

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine. However, the conventional nucleotide library preparation process has several challenges,

February 21, 2022

Nanoparticles: Emerging Stars for Pharmaceutical Industry

By Yash Kumar Nanoparticles 0 Comments

Over the last decade, one of the major challenges faced by pharmaceutical players across the globe is low drug solubility. In fact, it has been observed that around 40% of the pharmaceutical products approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the prime reasons that leads

February 19, 2022

Growing Demand for Oligonucleotides Proposes Shedload of Opportunities for Contract Manufacturers

By Dhriti Gulati Oligonucleotides 0 Comments

In the 20th century, major research went into discovery of a therapeutic class with the primary purpose of interfering with the RNA expression linked to disease causing proteins, nowadays classified as oligonucleotides. These short, single-stranded DNA or RNA molecules have various applications in biopharmaceutical and biotechnology industries including, genetic testing, basic research, forensic analysis and

February 18, 2022

MYELOID CELL TARGETING THERAPEUTICS: BUDDING THERAPY AGAINST CANCER

By Shivangi Anand Myeloid cell targeting 0 Comments

Myeloid cells represent a group of cells containing granulocytes, monocytes, macrophages, mast cells and dendritic cells, which play a key role in innate immunity. These cells are found in abundance in the tumor microenvironment and inflamed areas. The tumor recruits and modulates endogenous myeloid cells to tumor-associated macrophages, dendritic cells, myeloid-derived suppressor cells and neutrophils,

February 17, 2022

Shift in the trend of Container closure integrity testing

By Ridhima Gupta integrity testing 0 Comments

In earlier times, container closure integrity testing was not regarded as an essential step in the process of manufacturing. The company developing drug product through such an intense process, use to consider container closure system only for packaging of the product.[1] However, gradually it was realized that container closure integrity is a key factor that

February 16, 2022

Bringing in Light Genome Editing Techniques: ZFN, TALEN and Meganucleases

By Ishita Nanda Genome Editing Techniques 0 Comments

Presently, there are several companies and universities, which are exploring the potential of different gene editing technologies beyond CRISPR for basic research, and the development of gene editing solutions. With the development of a variety of versatile DNA modulation technologies such as include zinc-finger nucleases (ZFNs), TAL effector nucleases (TALENs), engineered endonucleases / meganucleases (EMNs)

February 15, 2022

ADC Cytotoxic Payloads / Warheads and Rise in its Demand

By Ishita Nanda ADC Cytotoxic Payloads 0 Comments

With six approved drugs, namely POLIVY™ (2019), LUMOXITI™ (2018), BESPONSA® (2017), MYLOTARG™ (2017, reapproval), KADCYLA® (2013) and ADCETRIS® (2011), and more than 300 candidates in the pipeline (clinical / preclinical stages), antibody drug conjugates (ADCs) have emerged as a promising class of therapeutics for the treatment of various disease indications. Over time, medical researchers have

January 6, 2022

Myeloid cell targeting therapeutics: Budding therapy against cancer

By Arun Gupta Myeloid cell targeting 0 Comments

Myeloid cells represent a group of cells containing granulocytes, monocytes, macrophages, mast cells and dendritic cells, which play a key role in innate immunity. These cells are found in abundance in the tumor microenvironment and inflamed areas. The tumor recruits and modulates endogenous myeloid cells to tumor-associated macrophages, dendritic cells, myeloid-derived suppressor cells and neutrophils,

January 4, 2022

Site management organizations: A deeper look into clinical trial site management landscape

By Rohit Pareek CLINICAL TRIAL PLANNING, Clinical Trials, Site Management Organizations, virtual clinical trials 0 Comments

Clinical trials form an integral part of the overall drug development process, enabling the necessary evaluation of the safety and efficacy of a drug candidate. Studies suggest that around 40% of the total investment made for the development of drug candidate is dedicated to clinical trials; this is equivalent to an expenditure of USD 78

January 3, 2022

At-Home Blood Collection: New Era of Diagnosis and Testing

By Simriti Gupta AT-HOME BLOOD COLLECTION, HOME BLOOD COLLECTION 0 Comments

In the era of COVID-19, where the world is looking for point of care treatment, in order to avoid maintain physical distance. Post the onset of COVID-19 pandemic, there has been a decline in number of patients visiting laboratories for sample collection and testing. To avoid risk of infections, patients have postponed their routine tests

December 28, 2021

Myeloid Cell Targeting Therapies: Budding Therapy Against Cancer

By Shivangi Anand Anti-cancer, Anti-cancer Therapy, cancer therapeutics, CELL TARGETING 0 Comments

The global cancer burden is increasing rapidly with over 19 million new cancer cases and 10 million deaths reported in the year 2020. Given the rising prevalence, researchers have made significant efforts in discovering new approaches for the treatment of oncological diseases. With several programs having entered the clinical stages, myeloid cell targeting therapies have

December 23, 2021

Regulatory T-cell Therapies: A Research Hotspot in the Field of Immunotherapy

By Ravneet Kaur Cell Therapies, Cell Therapy, T-Cell Therapies 0 Comments

Classification of Regulatory T-Cell Therapies The Regulatory T-Cell Therapies (Tregs) are a mature subpopulation of T-cells that play a critical role in mediating immunological tolerance to self-antigens and suppress immune responses that are harmful to the host, thereby, enabling homeostasis. These mainly develop in thymus from CD4+ thymocytes and are mainly of three types: natural

December 15, 2021

Site Management Organizations (SMOs): A Trending Term in the Clinical Trial Domain

By Rohit Pareek Clinical Practice, CLINICAL TRIAL PLANNING, Clinical Trials, Site Management Organizations, virtual clinical trials 1 Comment

Innovators in the pharmaceutical industry are constantly developing ways to improve the process of conducting clinical trials and managing research sites. Amidst other alternatives, outsourcing various trial operations to a specialized service provider, such as site management organizations (SMOs), has emerged as a viable option for various developers. The advantages of engaging such specialized service

December 14, 2021

IMPACT OF AT-HOME BLOOD COLLECTION AND MICRO SAMPLING DEVICES

By Simriti Gupta AT-HOME BLOOD COLLECTION 0 Comments

Earlier, approaches used for blood collection were invasive, time consuming and needed a healthcare expert. However, in recent years, the methods for blood collection are evolving at a rapid pace. According to research study, 69% of participant were found to take part more likely in clinical trials, if they are able to provide self-collected sample

December 13, 2021

DNA DATA STORAGE: RESEARCH LANDSCAPE AND FUTURE PROSPECTS

By Mansi Dhingra DATA STORAGE, DNA Encoded, DNA Manufacturing 0 Comments

DNA data storage involves encoding and decoding binary data to and from synthesized strands of DNA. It offers generous, long-lasting, and stable data storage solution with orders of magnitude relatively higher than current storage mediums. Owing to the numerous benefits offered by DNA data storage as compared to other mediums, it is anticipated that this

December 10, 2021

HER2 Targeting Therapies Market: A Deeper Look into Therapy Developer Landscape and Future Opportunities

By Ishita Nanda Anti-cancer, Anti-cancer Therapy, Cancer, cancer therapeutics, Targeting Therapies 0 Comments

The epidermal growth factor receptor (EGFR is a tumor resistance biomarker which plays an essential role in the differentiation and proliferation upon activation through the binding of one of its ligands. A non-ligand-binding member of EGFR family, HER2 exerts its activity through heterodimerisation along with its other family members. HER2 is a transmembrane growth factor

December 9, 2021

THE RISING REALM: BIOPRESERVATION MEDIA INDUSTRY

By Prachi Bhalla 3D Cell Cultures, BIOPRESERVATION 0 Comments

Biopreservation is the exclusive biological approach designated for the preservation of cells, tissues and organs ex-vivo for the purpose of storage, shipment and transportation. Biopreservation media is one of the most crucial entity in conferring effectiveness. The selection of the type of media depends upon the considerable time duration desired for the storage, type of

December 1, 2021

Cell and Gene Therapy Bioassay – A Prerequisite for the ATMPs Development

By Vaibhav Singh Bioassay, Cell Therapies, Gene Therapies 0 Comments

Bioassay – A Prerequisite for the Cell and Gene Therapy Development Over the past few years, investigational new drug (IND) filings for cell and gene therapy product have significantly increased. In fact, from year 2016 to 2020 more than 300 IND filing for cell and gene therapy product have been recorded, indicating that several developers

November 24, 2021

Rising Need of Large Volume Wearable Injectors

By Rupali Bhardwaj Injectors, Injectors Market, WEARABLE INJECTORS 0 Comments

With the increasing global population, the incidence rates of several chronic disease indications, such as diabetes, heart disorders, neurological disorders and oncological disorders, are on the rise. This has led to a rise in the demand for effective treatment options for patients suffering from these diseases. Further, in order to improve the quality of life

November 17, 2021

Pharmaceutical Vials Witnessing High Demand Due to COVID-19 Pandemic

By Simran Kaur COVID-19 Pandemic, Pharmaceutical Packaging, Pharmaceutical Vials, SUSTAINABLE PACKAGING 0 Comments

Over the years, advances in drug / therapy development processes have led the pharmaceutical industry to gradually shift from a one-drug treats all model to a more personalized approach of treatment. The growing complexity of modern pharmacological interventions, such as monoclonal antibodies, and cell and gene therapies, has further prompted the drug developers to develop

November 16, 2021

Fc Fusion Therapeutics – A New Approach to Drug Therapy

By Mansi Dhingra Antibody Discovery, Antibody Drug, Antibody Humanization, FUSION THERAPEUTICS 0 Comments

Since the approval of Enbrel®, CD4-Fc fusion protein (for the treatment of rheumatoid arthritis) in 1998, Fc fusion therapies have evolved into a prominent class of therapeutics.[1] Currently, 13 Fc fusion drugs are commercially available, while around 50 molecules are under development for various disease indications. Some of the Fc fusion therapeutics including Arcalyst® (recurrent pericarditis,

November 11, 2021

Pharmaceutical Vials Market: Current Scenario and Future Trends

By Simran Kaur Pharmaceutical Packaging, Pharmaceutical Vials, SUSTAINABLE PACKAGING 0 Comments

Primary packaging material (e.g. Pharmaceutical Vials) plays a crucial role in preserving the stability, efficacy and safety of the drug as it is in direct contact with the packaged therapeutic. Additionally, primary packaging material assists in maintaining the sterility and quality of a drug product, while also providing information related to its identity and, in

November 10, 2021

ADC Therapeutics – Alternative to Traditional Anticancer Therapies

By Ishita Nanda ADC Conjugation, ADC Therapeutics, ADCs Pipeline, Antibody Discovery, Antibody Drug, Antibody Humanization, Antibody Purification 0 Comments

Antibody-drug conjugates (ADCs) are an upcoming class of targeted therapeutic agents that have captured the attention of both large and small pharmaceutical companies, and academic / research institutions from all across the world. Fundamentally, these complex biotherapeutic entities demonstrate the combination of target specificity of an antibody and therapeutic features of a chemotherapy / cytotoxic

November 8, 2021

Glycoengineered Antibodies and Fc Protein – Virtue of enhanced effector functions

By Chaitanya Anand Antibodies, Antibody Discovery, Antibody Drug, Antibody Purification, Glycoengineered Antibodies 0 Comments

With close to 100 approved monoclonal antibodies, and over 550 molecules in the clinical pipeline, antibody based pharmacological interventions have become one of the fast growing segment of the biopharmaceutical industry.[1] In fact, these interventions are anticipated to generate a cumulative sales of USD 300 billion by 2025.[2] Further, within the antibody therapeutics industry, engineered

November 1, 2021

ADC Therapeutics – A Potential Tool Against Cancer

By Ishita Nanda ADC Conjugation, ADC Therapeutics, ADCs Pipeline, Antibodies, Antibody Drug 0 Comments

Over the years, various technological advancements, such as antibody engineering for site-specific conjugation and enhanced pharmacokinetic and pharmacodynamic properties, have paved the way for antibody drug conjugates (ADCs) to be recognized as potent therapies targeting a wide range of indications, including solid tumors and hematological malignancies. ADC Therapeutics are engineered therapies comprised of monoclonal antibodies

October 28, 2021

Sustainable Packaging: Paramount for Pharmaceutical Sector

By Nobel Dhingra Pharmaceutical Packaging, SUSTAINABLE PACKAGING 0 Comments

Sustainable Packaging in pharmaceutical industry plays a crucial role in ensuring the sterility and quality of a drug product, while it also provides information related to its identity and, in certain cases, dosing instructions. Pharmaceutical packaging is typically carried out under Packagingcontrolled conditions; specifically, for therapeutics that are designed for parenteral administration, fill / finish

October 26, 2021

Alzheimer’s Disease and Its Evolving Market

By Sunidhi Thakur Alzheimer's Disease, Alzheimer's Pipeline, Alzheimer’s Disease 0 Comments

Alzheimer’s disease is a progressive neurological disorder characterized by the death of brain cells, eventually leading to memory loss, cognitive dysfunction and dementia. Accounting for 60-70% cases of dementia, Alzheimer’s disease is known to be the sixth leading cause of death in the US. Presently, more than 6 million Americans of all ages are living

October 25, 2021

Cell Therapy Packaging – Importance and Future Perspective

By Shivangi Anand Cell Therapy, Pharmaceutical Packaging 0 Comments

Over the years, the pharmaceutical industry has witnessed several advancements in drug development. It has gradually shifted from a one-drug treats all model to a more personalized approach of treatment, which involves the use of personalized cell therapies for various disease indications. This shift has led to an evident change in the pharmaceutical packaging domain

October 22, 2021

Progressive Supranuclear Palsy (PSP): A Tough Nut to Crack

By Ishita Nanda Supranuclear Palsy 0 Comments

Since John Steele, John Richardson, and Jerzy Olszewski first described Progressive Supranuclear Palsy (PSP) in 1964, the neuroscience community has been on the lookout to find a “miracle molecule” or an “elixir” that can cure patients diagnosed with this debilitating disease. With more than 2,000 research studies published so far, the domain has garnered significant

October 12, 2021

Teleradiology: The Need of The Hour During COVID-19 Pandemic

By Gaurav Raj artificial intelligence, Digital Therapeutics, Patient Monitoring, TELERADIOLOGY 0 Comments

Teleradiology is a branch of telemedicine that uses telecommunication systems for the transmission of radiological images from one location to another. Additionally, it helps the radiologists to interpret various types of images, such as computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), ultrasound, and X-rays, remotely. As of late, teleradiology has piqued

September 27, 2021

Bioprocess Automation: A Step Towards Digital Transformation

By Ridhima Gupta BIOPROCESS AUTOMATION 0 Comments

In the era of digitalization where the world is looking forward towards automating their manufacturing process, the bioprocess industry took a while to adopt the automation technology. The biopharmaceutical industry came across several obstacles while adopting the automated technology. Examples of which include, complexity of the processes and delicacy of the living cells and organisms

September 23, 2021

Novel Drug Reconstitution Systems: Opportunities in Accurate Reconstitution and Drug Delivery

By Diksha Agarwal Drug Delivery, Drug Reconstitution 0 Comments

The novel drug reconstitution systems have emerged as a promising alternative to traditional methods of reconstitution, adding significant value to the storage and transfer of lyophilized therapeutics. These systems enhance the portability, efficiency and optimum delivery of the lyophilized drugs and have the potential to reduce the number of steps significantly, which enable the dilution

September 21, 2021

Key Facts About Bioprocess Controllers and Automation Systems Market

By Ridhima Gupta BIOPROCESS CONTROLLERS 0 Comments

For further information on this domain, check out the report – Roots Analysis – Report You may also be interested in the following titles: Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031 Fc Protein and Glyco-engineered Antibodies Market: Focus on Type of Fc Engineering and Therapeutics (3rd edition), 2021-2030 Bronchial Spasm: Pipeline Review,

September 20, 2021

Novel Drug Reconstitution Systems: Emerging Options for the Reconstitution of Lyophilized Drugs

By Diksha Agarwal Drug Reconstitution, NOVEL DRUG 0 Comments

Lyophilization of Pharmaceuticals and Drug Reconstitution In 2018, seven out of ten top-selling prescription medicines were biologics. The liquid formulations of biologics are not much stable and tend to loose efficacy with time due to the changes in their pharmacokinetic and pharmacodynamic properties. Therefore, lyophilization of such drugs is essential before their storage. Around 50%

September 16, 2021

Squamous Non-Small Cell Lung Cancer Market: Current Scenario and Future Trends

By Abhishek Dogra Cancer, CANCER MARKET, cancer therapeutics, Novel Cancer 0 Comments

Close to 1.8 million fatalities reported in 2020 were observed to be associated with lung cancer, which is believed to be one of the most aggressive forms of carcinoma, globally. One of the primary reasons for the high mortality rate associated with this condition is anticipated to be late diagnosis, which eventually results in delayed

September 14, 2021

Pharmaceutical Contract Manufacturing and The Rising Adoption of Sophisticated Processes

By Simriti Gupta BIOMANUFACTURING, Contract Manufacturing, Manufacturing 0 Comments

Recent developments in pharmacology and biotechnology have been able to drive significant advances and innovation in understanding the root causes of various diseases; this has further aided in the discovery and development of more targeted treatment strategies. It is worth noting that such advances in the healthcare industry have made pharmaceutical development and contract manufacturing

September 13, 2021

Remote Patient Monitoring: A Paradigm Shift in Healthcare System

By Sayoni Banerjee Patient Monitoring 0 Comments

The development of the concept of remote patient monitoring (RPM) started nearly 200 years ago in 1800s. However, it wasn’t until the introduction of cloud computing, that the domain evolved at a significant pace. In fact, RPM solutions are gradually being integrated into mainstream healthcare systems; specifically, during the COVID-19 induced lockdown, such advanced tools

September 8, 2021

Squamous Non-Small Cell Lung Cancer Market: An Emerging Treatment Modality

By Abhishek Dogra CANCER MARKET, Immunotherapy 0 Comments

Over the years, a number of targeted therapies have been developed for the treatment of various type of cancers, with the primary focus on the safety and efficacy of the treatment. The uncontrolled growth of cells originating in the bronchi lining, bronchioles or alveoli of the lungs is termed as lung cancer. Around 85% of

September 2, 2021

Clinical Trial Planning and Design Services Market: What Does the Future Hold?

By Bhavishya Bhardwaj CLINICAL TRIAL PLANNING, Clinical Trials, virtual clinical trials 0 Comments

Over the years, clinical research has undergone an evolutionary change, in terms of cost of research, technology used, and duration of the study. It is worth highlighting that clinical research involves two major steps, namely study design and study reporting. Further, study design involves three key steps, theoretical design, data collection design and statistical analysis

August 17, 2021

Pharmaceutical Contract Manufacturing: The Solution to Production of Complex Substances

By Simriti Gupta Contract Manufacturing, Manufacturing, Market Research, Pharmaceuticals 1 Comment

The inherent expertise of CMOs and CDMOs is believed to be capable of enabling reduction in the time-to-market a product, significant cost-benefits, as well as access to larger production capacities and novel technologies. It is worth mentioning that there has been substantial merger and acquisition activity in the pharmaceutical contract manufacturing market in the past

July 12, 2021

Display Library Technologies: Where do we stand?

By Sunidhi Thakur Display Library Technologies 0 Comments

Over time, a variety of methods / approaches have been developed for the generation of viable therapeutic leads. These include the hybridoma technology, B-cell cloning, transgenic animal-based techniques, in vitro display methods (using phages, ribosomes, mRNA, and cDNA) and cell surface display methods (involving mammalian, yeast, and bacterial cells). Despite being responsible for the development

June 29, 2021

Target Protein Degradation – Transformative Approach to Selectively Eliminate Disease-Causing Protein

By Nancy Kapila Target Protein Degradation 0 Comments

Targeted protein degradation is an emerging therapeutic modality that has the potential to enable the treatment of difficult-to-treat diseases. While conventional medicines, such as small molecule inhibitors and monoclonal antibodies, address fewer than 20% of the proteome, TPD offers a unique means to tap into the rest of the vast, unexplored proteome. Through TPD, a

June 22, 2021

Nothing Ventured, Nothing Gain: Bringing to Light The Continuous Manufacturing Equipment Providers

By Shivangi Anand BIOMANUFACTURING, Contract Manufacturing, Manufacturing, Microbial Manufacturing 0 Comments

Over the years, several industries have implemented evolutionary changes in their respective manufacturing processes. One to the most rewarding advancements in this direction, is process automation. In pharmaceutical manufacturing, the automation of various aspects of the production process has led to the establishment of the continuous manufacturing paradigm. However, the transition to continuous manufacturing is

June 21, 2021

Polycystic Ovary Syndrome (PCOS)

By Nancy Kapila Polycystic Ovary Syndrome 2 Comments

Polycystic Ovary Syndrome is a condition in which the ovaries produce abnormal amount of androgens (males sex hormones), higher than the amount usually present in a woman with normal ovaries. The ovaries develop fluid filled sacs, known as follicles, which contain an immature egg. However, in polycystic ovary syndrome, none of the eggs mature and

June 16, 2021

Cell Line Development and Characterization: An Ocean of Opportunities for Service Providers

By Jasparam Kaur 3D Cell, 3D Cell Cultures, Cell Line, Cell Line Development, Cell Therapies, Cell Therapy 1 Comment

The growing pipeline of monoclonal antibodies, vaccines, enzymes, biosimilars and other therapeutic proteins have created an ever- increasing demand for highly- productive and stable cell lines. Many of the recombinant biotherapeutic products, produced in cellular systems, have been translated into commercial successes; these include ALPROLIX®, ELOCTATE® and ELAPRASE®. Given their impact on the overall quality

June 15, 2021

Modular Facilities: A Paradigm Shift in Pharmaceutical Facility Design

By Yuveena Singh BIOMANUFACTURING, Contract Manufacturing, DNA Manufacturing, Manufacturing, Microbial Manufacturing, MODULAR FACILITIES, Vector Manufacturing 1 Comment

The concept of modular building has long been employed in other sectors, but it has only recently acquired traction in the pharmaceutical business over the last two to three decades. Modular construction is a process wherein factory-produced, pre-engineered building units, which are constructed offsite under controlled plant conditions, are assembled on site to construct the

June 14, 2021

Intracellular delivery technologies – solution to undruggable targets

By Chaitanya Anand Modern pharmaceutical industry 1 Comment

Over time, advances in molecular biology and pharmacological chemistry have enabled the identification of biological targets localized in the subcellular space, and development of therapeutic leads against them. In fact, there are several clinical conditions, which were previously considered undruggable since the traditional small molecule-based interventions were unable to penetrate the selectively permeable cell membrane.

June 11, 2021

Antibody Purification: A Deeper Look into Service Providers Landscape

By Ishita Nanda Antibody Drug, Antibody Purification 0 Comments

Over time, several innovative technologies have been developed to support the designing and manufacturing of various types of antibody products; however, the aforementioned processes are characterized by high costs and technical complexities, especially during the production and downstream processing steps. Therefore, it is challenging for new entrants and companies with limited resources and capital, to

June 10, 2021

Antisense Oligonucleotides – The Revolutionizing Modalities in the Field of Gene Silencing

By Mansi Dhingra Antisense Oligonucleotide, Oligonucleotides 1 Comment

Oligonucleotide (commonly referred to as oligos), are short single stranded DNA or RNA molecules, typically containing 15-20 nucleotide residues.[1],[2] In the modern biopharmaceuticals and biotechnology, the applications of these molecules are vast, including (but not limited to) genetic testing, fundamental biomolecular research, and forensic analysis. Oligonucleotides are a diverse class of therapeutics that are divided

June 9, 2021

Non-Invasive Diagnostics for Fibrotic Disease Market: A Step Towards Painless and Specific Detection of Fibrosis

By Ishita Nanda Non-Invasive Diagnostics 1 Comment

Advances in the field of biotechnology have enabled the development of several minimally invasive / non-invasive approaches for diagnosis of fibrotic diseases which include imaging diagnostics and biomarker-based assays. Among the biomarker-based tests, liquid biopsy (based on the analysis of biofluids such as blood, urine and / or plasma), a relatively new concept, has emerged

June 8, 2021

Targeting the STING Pathway

By Shivangi Anand Market Research, STING Pathway 1 Comment

Stimulator of interferon genes or STING, discovered by the laboratory of Glen N Barber in 2008, is one of the signaling proteins that is responsible for the transcription of genes associated with the innate immunity of an individual. Amidst the recent COVID-19 pandemic, it has become even more essential to strengthen the immune system. The

June 7, 2021

Immunocytokines – The Power of Fusion Proteins

By Ishita Nanda Immunocytokines, Market Research, Proteins 1 Comment

Cancer is one of the leading causes of death worldwide, accounting for an estimated 0.6 million deaths in 2020, in the US alone. The World Health Organization has estimated the number of new cancer cases to rise by 70%, worldwide, over the next 20 years. It is a well-known fact that the conventional treatment options,

March 2, 2021

Virtual Clinical Trials: The Present And Future Of Pharmaceutical Research

By Simriti Gupta Clinical Trials, virtual clinical trials 1 Comment

The lack of patient centricity in traditional clinical trials is known to inhibit trial sponsors to retain enough patients, which is critical to successfully complete safety and efficacy evaluations of novel therapeutic interventions on predetermined completion dates. In addition, the lack of participant compliance in clinical trials often leads to massive delays which are known

February 26, 2021

Biopharmaceutical Contract Research Organizations: Fueling the research of novel biologics

By Bhavishya Bhardwaj Biopharmaceutical, Contract Research Organizations, Contract Service Providers 1 Comment

Biologics, often referred to as biopharmaceuticals or large molecules, are manufactured in the biological system, such as microorganisms, plants, or animal cells. Biologics represent one of the fastest growing segments of the pharmaceutical industry. This can be attributed to the rapid pace of innovation in this field, driven by the need for effective and personalized

February 16, 2021

Outlook for the contract manufacturing industry following the growing biologics pipeline

By Jasmeet Bhalla BIOMANUFACTURING, Contract Manufacturing, Manufacturing, Microbial Manufacturing, Vector Manufacturing 1 Comment

The recent years have portrayed the renaissance in the domain of biologics, as pharmaceutical industry has once again gained attention towards the production of bioproducts. In fact, in 2019, a total of 28 biopharmaceutical products (including monoclonal antibodies, recombinant proteins and gene therapies) were approved in the US. Further, over 8,000 biological pharmaceutical products are

February 15, 2021

Digital Biomarkers: Is Efficient Remote Monitoring of COVID-19 Patients Primary Reason for Incessant Rise in Demand?

By Yash Kumar Biomarkers 0 Comments

Biomarkers or biological markers are distinctive physiological features in an individual, which can be detected and quantified in order to gain insights about health and disease. On the other hand, digital biomarkers are defined as digital means that are employed to collect data about these unique biomarkers. These are combination of hardware and software features,

February 9, 2021

Artificial Intelligence in Drug Discovery – Could help Reduce Significant Capital and Time Required

By Ajay Kumar artificial intelligence, Drug Discovery 0 Comments

Drug discovery is a complex process which involves significant utilization of time and resources. As per several sources, on an average, the entire drug development process (from initial proof-of-concept to commercial launch) takes around 10-15 years and capital investments worth USD 4-10 billion to develop a drug from concept to commercial launch. The early stages

February 4, 2021

mRNA: the Higgs boson of modern medicine?

By Avin Kakkar mRNA, Vaccines 1 Comment

Messenger RNA (mRNA) is a single-stranded molecule, which is complementary to the DNA strands of a gene. It plays a prominent role in the process of protein synthesis, wherein mRNA is responsible for transferring genetic information from DNA to ribosomes, a specialized structure, or organelle, which decodes genetic information into a protein. In the last

February 3, 2021

Advancing Healthcare Delivery via Artificial Intelligence

By Ajay Kumar artificial intelligence, Drug Discovery 0 Comments

Artificial Intelligence have demonstrated intelligent behavior through their ability to learn, communicate with its users and solve complex problems using highly sophisticated algorithms. AI-driven technologies have continued to evolve rapidly, with several industries increasingly deploying such solutions across key aspects of value chain. Furthermore, AI is also made with same idea of making tasks simpler

January 6, 2021

Antibody Drug Conjugates (ADCs): A Deeper Look into Contract Manufacturing Landscape

By Gaurav Chaudhary ADC Conjugation, ADC Therapeutics, ADCs Pipeline, Antibody Drug, Therapeutics 1 Comment

Antibody Drug Conjugates (ADCs) known as the 21st Century Magic Bullets, have emerged as a promising class of targeted therapies being developed for the treatment of cancer. Two decades ago, in the year 2000, the domain witnessed the approval of first ADC known as Mylotarg®, by the US FDA. This was followed by the successful

December 21, 2020

Single-Cell Sequencing: The New Era of Gene Expression Analysis

By Simriti Gupta Market Research, Pharmaceuticals, SINGLE CELL SEQUENCING 1 Comment

For developing an improved understanding of the interactions of individual cells within their microenvironment, advanced molecular probing solutions are being used by researchers across the globe. In this context, high-throughput single-cell analysis, has emerged as a powerful analytical technique for studying individual cells, enabling researchers to study gene expression at single cell resolution. Single-cell sequencing

October 27, 2020

Harnessing The Power of Real World Evidence to Fight COVID-19 Pandemic

By Nancy Kapila COVID-19, Market Research, Pharmaceuticals, Real World Evidence, RWE 1 Comment

HARNESSING THE POWER OF REAL WORLD EVIDENCE TO FIGHT THE COVID-19 PANDEMIC

With the ongoing pandemic of COVID-19, there is long wait for the vaccine to be approved. Even after the vaccine gets approved, there is no assurance of the complete eradication of virus. There will still be percentage of people who contract the illness. Therefore, it is very important to trace and detect the treatments in

October 26, 2020

Microbial Contract Manufacturing: Growing Microbial-Based Biologics Pipeline Boosts The Market

By Simriti Gupta BIOMANUFACTURING, Contract Manufacturing, Manufacturing, Microbial Biopharma Industry, Microbial Manufacturing 1 Comment

The recent years have portrayed the renaissance in the domain of microbial fermentation, as microbial biopharma industry has once again gained attention towards the production of biologics using microbial expression system. The modification and innovation in the microbial expression systems for the production of various biologics have side-lined some of the earlier concerns associated with

October 20, 2020

REAL-WORLD EVIDENCE: THE GAME CHANGER IN DRUG DEVELOPMENT

By Nancy Kapila DRUG DEVELOPMENT, Pharmaceuticals 1 Comment

Pharmaceutical and Life Sciences Real World Evidence

While the definition of real world evidence is still evolving, most proponents associate it with data that is derived from medical practice among heterogeneous sets of patients in the real world setting. It is the integration of data gathered from various sources, such as EHRs, medical charts, patient claims and billing activities, product and disease

October 19, 2020

Are Handheld Ultrasound Imaging Devices a True Revolution in Diagnostic Imaging Domain?

By Ronit Sharma Diagnostics, Market Research, Ultrasound 0 Comments

Advancements in the field of disease diagnostics have led to development of point-of-care medical imaging devices; handheld ultrasound scanners have emerged as a novel solution to cater to unmet need in this domain. These handheld ultrasound imaging devices are the lightest portable ultrasound devices, which permit patient diagnosis from a single transducer and transmit images

October 14, 2020

3D Cell Cultures: Rejuvenation amidst COVID-19

By Abhishek Dogra 3D Cell, 3D Cell Cultures, COVID-19, Market Research 1 Comment

As per the experts, one of the key reasons for the failure of therapeutic candidates in clinical trials is the use of conventional 2-dimensional (2D) cell culture systems in early research studies. The 2D systems are severely limited in a number of aspects. For instance, only 50% of the cell surface is exposed to the

October 13, 2020

Digital Therapeutics: Key Concepts and Regulations to Tackle COVID-19 Pandemic

By Yash Kumar COVID-19, Digital Therapeutics, Therapeutics, therapeutics market 1 Comment

Digital therapeutics are clinically validated applications / software / online programs that have demonstrated the capability to facilitate positive outcomes when used in the prevention / treatment / management of diseases / clinical conditions. These therapeutics are designed to engage patients in personalized treatment or disease prevention programs, through mediating behavioral or psychological modifications, providing

October 12, 2020

Inhaled and Intranasal Drug Delivery: A Deeper Look into Service Providers Landscape

By Ankita Kashyap Inhaled and Intranasal Drug Delivery, Market Research, Pharmaceuticals, Service Providers 1 Comment

Inhaled and Intranasal Products: Contract Service Providers Market

The techniques used for the drug delivery are found to be have an enormous impact on the efficacy of the treatment. In fact, the slow progression of the efficacy, has suggested the need of different approaches for the effective delivery of drug to the target area, along with the optimal bioavailability. Over the years, several

October 7, 2020

Targeted Drug Delivery Devices: An Attractive Option for Improving the Efficacy of Biologics

By Gaurav Chaudhary Biologics, Drug Delivery, Medical Device, Medical Devices and Technology 1 Comment

The gradual shift of healthcare industry towards the development of biologics is a well-known fact. Owing to this shift, there are over 1,000 cell and gene therapies which are being developed for the treatment of various disorders, majority of them being oncological disorders, cardiovascular disorders and neurological disorders. Additionally, over the last decade, multiple immunotherapies

September 17, 2020

Single-Use Bioreactors on Rescue for COVID-19 Research

By Sayoni Banerjee Bioreactors, COVID-19 1 Comment

The development of single-use bioreactors started nearly 40 years ago in 1980s. It was around this time that the bio-processors began to use plastic film bags to culture cells, which were initially designed for food storage and culture media containment. Moreover, incremental evolution of the concept of disposable technologies have facilitated various advancements in development

September 8, 2020

Nuclear Medicines And Radiopharmaceuticals: Redefining The Use Of Radioactivity In Modern Day Healthcare

By Gaurav Chaudhary RADIOPHARMACEUTICALS 1 Comment

Fostered by partnerships between national laboratories, academia, and the pharmaceutical industry, the field of nuclear medicines and radiopharmaceuticals has evolved over the past few decades, in parallel with advances in imaging instrumentation, radionuclide production, and radiopharmaceutical development. Nuclear reactors and particle accelerators are presently used to produce a wide array of radionuclides for diagnostic and

September 7, 2020

Will the Renascence of Microbial Manufacturing be Impacted by the Pandemic?

By Simriti Gupta Contract Manufacturing, Microbial Manufacturing 1 Comment

Since the discovery of recombinant DNA technology, several types of microbes have been established as a versatile biomolecule expression system. This can be attributed to the ease of handling of microbial cell lines, which are considered less fragile (compared to cells of higher eukaryotes); rendering them a popular choice for manufacturing operations. Moreover, incremental evolution

August 11, 2020

Drug Repurposing – A Deeper Look into Service Providers Market

By Jasmeet Bhalla Drug Repurposing, Service Providers 1 Comment

Over the past decade, several scientific and technological breakthroughs in the drug repurposing industry have resulted in an accelerated pace of research and innovation within this domain. Further, the demand for effective repurposed therapies in the on-going war with the pandemic, is on the rise. However, one of the primary challenges faced by this industry

July 31, 2020

Outsourcing: An Attractive Option For Antibody Production

By Simriti Gupta Market Research, therapeutics market 1 Comment

In recent years, contract manufacturers have become an integral part of the overall biopharmaceutical market. This trend is also gaining popularity within the antibody therapeutics market, as developers are increasingly outsourcing their antibody production requirements to contract service providers. This can be attributed to the fact that employing such third-party service providers offers various advantages,

July 28, 2020

Large Volume Wearable Injectors: A breakthrough to simplify Chronic Disease Management

By Ishita Nanda Injectors, Injectors Market 1 Comment

The last few years have witnessed a rising incidence of chronic illnesses across the globe. Long term clinical conditions, such as neurological disorders, cardiovascular disorders, chronic pain and oncological disorders, have been shown to impose a significant burden on the modern healthcare system and those who suffer from such diseases. It is reported that about

July 27, 2020

Significant Potential of Gut Flora: Human Microbiome

By Nancy Kapila Human Microbiome 1 Comment

Human Microbiome Therapies are Viable Alternatives to Antibiotics, with Substantial Therapeutic Potential The term microorganisms was perceived to be synonymous to harmful, disease causing agents, until the discovery of certain beneficial microbial colonies in the human system. Currently, humans and a variety of species of bacteria, yeast and protozoa, are known to co-exist in mutually

July 23, 2020

The Evolving Dynamics of Large Volume Wearable Injectors Market

By Ishita Nanda Injectors, Injectors Market 1 Comment

The field of self-injection devices has witnessed a lot of innovation in the recent years. Specifically, , large volume wearable injectors are certainly a boon due to their ability to address challenges associated with the administration of high volume formulations, viscous drug solutions and cater to frequent dosing requirements of patients suffering from chronic health

July 22, 2020

Healthy Microbiome: Fighter Against COVID-19

By Nancy Kapila Covid19, Healthy Microbiome 1 Comment

The COVID-19 pandemic is spreading to every corner of the world. During this worldwide attack of virus, human beings are highly concerned for their immune system, since it is the only savior currently. In circumventing a response to pathogenic infections like coronavirus, a healthy microbiome is essential to maintain an optimal immune system in preventing

July 22, 2020

Will the Drug Repurposing Industry Boom due to the Pandemic?

By Jasmeet Bhalla Drug Repurposing 1 Comment

Since, the outbreak of novel coronavirus, drug repurposing has become one of the core research strategies for finding a treatment. Several clinical studies for the already approved drugs, have been registered in order to identify cure for the novel coronavirus infection. It is known that on an average, it takes around 12 to 15 years

July 17, 2020

Medical Device CROs – The next Growth Opportunity

By Simriti Gupta Medical Device 1 Comment

Over the past decade, numerous scientific and technological breakthroughs in the medical device industry have resulted in an accelerated pace of research and innovation within this domain. Further, the demand for high quality and efficient medical devices, driven by a growing geriatric population and increasing incidence of various chronic clinical conditions, is on the rise.

July 9, 2020

Fill / Finish Services Industry: Impact of the Swelling Biopharmaceutical Pipelines

By Gaurav Chaudhary Biopharmaceutical, Biotech 1 Comment

Biopharmaceuticals represent the most rapidly growing and high-value segment of the pharmaceutical industry. Growing at an annualized rate of ~12%, the industry stands tall with more than 5,000 biologics in development and over 300 FDA approved biologics, since 2002. Biologic drug development is characterized by high quality standards and a rapidly growing demand for novel

July 8, 2020

In Vitro ADME Testing Services: Emerging Opportunities for Service Providers

By Gaurav Chaudhary Market Research, Testing Services 0 Comments

According to the US Food and Drug Administration (USFDA), less than 10% of investigational new drug (IND) candidates progress beyond the submission of a new drug application (NDA); this implies that majority of the drug / therapy candidates fail to reach the market owing to unacceptable safety and efficacy profiles and the problems associated with

July 8, 2020

Increasing Prevalence of Chronic Diseases- Driving the Demand for Self-Administration Devices, Like Autoinjectors

By Gaurav Chaudhary Autoinjectors, Drug Adherence, Medical Device, Medical Devices and Technology, Therapeutics 0 Comments

Over the last decade, autoinjectors have emerged as a promising therapeutic commodity for safe administration of parenteral therapies. Patients who suffer from chronic diseases, such as diabetes, rheumatoid arthritis and multiple sclerosis, often require frequent dosing of medication which poses significant inconvenience to them for visiting proper healthcare centers. Hence, autoinjector devices enable such patients

July 3, 2020

Peptide APIs – A Deeper Look Into Contract Manufacturing Market

By Simriti Gupta Contract Manufacturing, Manufacturing 1 Comment

The recent years have portrayed the renaissance of peptide APIs, as pharma industry has once again turned its attention towards the potential of therapeutic peptides. Adoption of peptides as therapeutic agents have side-lined some of the earlier concerns associated with them, such as bioavailability, and has led to manufacturing of high-quality peptides in a larger

July 3, 2020

Increasing Rate of Drug Failure has Prompted the Drug Developers to Rely on CROs offering In Vitro ADME Testing Services for their Outsourcing Requirements

By Gaurav Chaudhary ADME Testing, Drug Discovery 1 Comment

It is important to note that the process of drug discovery is extremely demanding, both in terms of capital and time. In fact, the overall amount spent on R&D initiatives in the pharmaceutical / biotechnology sector has increased from around USD 128 billion in 2008 to USD 165 billion in 2018. Moreover, only a small

June 25, 2020

Targeted Protein Degradation is Anticipated to Become a Major Therapeutic Modality in the Coming Decade

By Gaurav Chaudhary Protein Degradation, Therapeutics 1 Comment

The targeted protein degradation approach is believed to possess the potential to unlock the undruggable proteome, which was traditionally considered to be inaccessible. Compared to conventional inhibition strategies, degradation offers several benefits, which include the opportunity to completely remove aberrant proteins and associated systemic malfunctions. As a result, targeted protein degradation-based therapeutics have generated enthusiasm

June 25, 2020

Rising Popularity of Drug Targeting Synthetically Lethal Targets Fuels the Battle of PARP Inhibitors for Treatment of Advanced Cancer Indications

By Gaurav Chaudhary Cancer, cancer therapeutics 1 Comment

Cancer is considered to be the second leading cause of mortality, after cardiovascular diseases, accounting for every sixth reported death in the world. The International Agency for Research on Cancer (IARC) states that the number of new cancer cases is expected to grow to 27.5 million across the globe, by 2040. Experimental evidence has shown

June 23, 2020

Cell Therapy: A Potential Treatment for COVID-19?

By Simriti Gupta Cell Therapy, COVID-19 1 Comment

With the success of first vaccine to reach phase I clinical trial and turning out to be safe, well-tolerated, and capable of generating an immune response against the virus in humans, a lot of hope has been created with this vaccine. However, the research is still ongoing to develop novel therapeutic treatments that could aid

June 23, 2020

Targeted Protein Degradation – Defining a New Frontier in the Field of Medicine

By Gaurav Chaudhary Drug Discovery, Protein Degradation 1 Comment

The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. While conventional medicines, such as small molecule inhibitors and monoclonal antibodies, address fewer than 20% of the proteome, targeted protein degradation offers a unique means to tap into the rest of the

June 22, 2020

In Silico / Computer-Aided Drug Discovery Service Providers for Large Molecules

By Nancy Kapila Drug Discovery 1 Comment

Over time, the complexities associated with drug discovery have increased, especially in case of large molecule drugs, which are inherently more complex than conventional small molecules. As a result, an increase in the overall research and development (R&D) expenditure in the pharmaceutical / biotechnology sector has been witnessed. In addition to the complexities involved, the

June 22, 2020

Computational / In Silico Drug Discovery: A Boon in Disguise for Faster Drug Discovery Operations Amidst COVID-19

By Gaurav Chaudhary COVID-19, Drug Discovery 1 Comment

The COVID-19 pandemic is predicted to throw the global economy into recession, with loss of trillions of dollars. The pharmaceutical industry cannot escape the brunt of the circumstances as well. In fact, according to a survey, 95% of healthcare industry professionals are worried about the impact the pandemic is likely to have on the industry. So far,

June 18, 2020

Liquid Biopsy – The Beginning of a New Era in Cancer Diagnostics

By Ishita Nanda Cancer, Liquid Biopsy 1 Comment

Cancer is known to be one of the leading causes of death worldwide. In 2019, 0.6 million deaths due to cancer are estimated in the US alone. Moreover, the World Health Organization has estimated the number of new cancer cases to rise by 70% over the next 20 years. One of the primary reasons for

June 18, 2020

Next Generation Immune Checkpoint Inhibitors and Stimulators: Another Big Opportunity

By Ishita Nanda cancer therapeutics, Therapeutics 1 Comment

There is an urgent unmet need for developing innovative and effective cancer therapeutics for the treatment of patients with late-stage and refractory cancer. Amidst the widespread initiatives to develop more targeted anti-cancer therapies, immune checkpoint inhibitors emerged as a highly specific and potent option to eradicate tumor cells with minimal side effects. Once the body

June 17, 2020

Favorable Demand Dynamics within the Ophthalmic Drugs Contract Manufacturing Market

By Abhishek Dogra Contract Manufacturing, Manufacturing, Ophthalmic Drugs 1 Comment

In the past two decades, advances in optometry, along with an increased understanding of human eye and vision care, have led scientists to develop innovative treatment methods in order to treat eye disorders and to overcome the limitations offered by conventional medical practices. The current ophthalmic diseases treatment landscape is characterized by a number of

June 17, 2020

Outsourcing has become a popular trend in ophthalmic drug development domai

By Gaurav Chaudhary Contract Manufacturing, Ophthalmic Drugs 1 Comment

Ophthalmic Drugs Contract Manufacturing Market

Owing to various reasons, such as growing manufacturing demand, need for specialized facilities, equipment and operational expertise, and high costs of development associated with certain drugs / therapies, a number of innovator companies have demonstrated a preference to outsource certain aspects of ophthalmic drug development and production operations to contract service providers. Over 240 companies

June 17, 2020

Microbiome-based Live Biotherapeutics Contract Manufacturing: Rising Opportunities for Specialized CMOs / CDMOs

By Gaurav Chaudhary Contract Manufacturing, Microbiome Research 1 Comment

What is the current development pipeline of microbiome-based live biotherapeutics? With over 85 products under preclinical and clinical development, the current development pipeline of microbiome-based live biotherapeutics has several promising candidates, which are anticipated to get commercialized over the next few years. Hence, the demand for R&D and manufacturing services for such products is anticipated

June 11, 2020

RISE OF ANTIBODY DRUG CONJUGATES WITH THE RECENT APPROVALS

By Ankita Kashyap Antibody Drug, Healthcare, Pharmaceuticals 1 Comment

Antibody drug conjugates (ADCs) have captured the attention of both large and small pharmaceutical companies, and academic / research institutions, for more than a decade. For the past few years, several failures of clinical trials were blamed for the lack of interest of some companies in this therapeutic approach. However, after a decade-long dribble of

June 11, 2020

Needle-free Injection System: A light bearer in the fight against the thick darkness of COVID-19

By Ishita Nanda Coronavirus, COVID-19, Medical Device, Medical Devices and Technology 1 Comment

The apocalyptic images of the COVID-19 induced locked-down world are heart wrenching. All healthcare related domains are being created at a rapid rate. Around the world, the coronavirus pandemic is overstretching health services and reportedly more than 40 companies have boosted their R&D efforts to hit the bulls eye and deliver the much awaited vaccines

June 8, 2020

CRISPR Can be a Solution to Address the COVID-19 Pandemic

By Gaurav Chaudhary Coronavirus, COVID-19, Diagnostics 1 Comment

As we know, COVID-19 is causing large scale loss of life and severe human suffering. With the pandemic spreading across the globe, researchers are racing against the clock to develop diagnostic tools, vaccines and treatments. Recently, WHO has launched a Solidarity clinical trial to assess relative effectiveness of four potential drugs against COVID-19. Further, there

June 4, 2020

ASCO 2020: AstraZeneca Presents a Game-Changer in Lung Cancer

By Gaurav Chaudhary Cancer 1 Comment

While the ASCO 2020 presentation was virtual this year, the phase III results from AstraZeneca’s drug Tagrisso, in lung cancer patients, were as real as they could get. 89% of patients treated with Tagrisso were alive and cancer-free after two years, compared to 53% of patients treated with the placebo. Oncology Dominance AstraZeneca started with

June 2, 2020

Growing Pipeline of Microbiome-based Live Biotherapeutics Fuels the Manufacturing Demand

By Gaurav Chaudhary Biotherapeutics, Manufacturing, Microbiome Research 1 Comment

Live biotherapeutics are fragile bacteria, which require ideal conditions of heat, moisture and pH of products, to survive and prevent premature germination. In fact, manufacturing is presently one of the biggest bottlenecks in this domain; manufacturing such products is both technically challenging and financially demanding. One of the biggest challenges in the development of a

May 26, 2020

Growing Oligonucleotide-based Drugs Pipeline Escalates Manufacturing Demand

By Gaurav Chaudhary COVID-19, Oligonucleotides 2 Comments

As therapeutic agents, oligonucleotides are known to be associated with several unique features, such as high selectivity and potency (similar to biologics), and differentiated pharmacology, which further augment their drug-like properties. At present, eight oligonucleotide-based drugs are available in the market, namely (in reverse chronological order of year of approval) GIVLAARI™ (2019), ONPATTRO® (2018), TEGSEDI™

May 25, 2020

Response to COVID-19 Pandemic with Oligonucleotides

By Gaurav Chaudhary COVID-19, Covid19, Oligonucleotides 1 Comment

Never before, scientists say, the universal community of researchers have put a halt to all other ongoing research and have urgently focused towards swiftly evolving health emergency. In the past few months, scientists have been repurposing their research efforts towards contributing to the global effort in response to COVID-19 pandemic. For the purpose of mitigating

May 20, 2020

How COVID-19 Poses a Sharp Challenge on China Biopharmaceutical Contract Manufacturing Market?

By Simriti Gupta Biopharmaceutical, Contract Manufacturing, COVID-19 1 Comment

China, epicenter of the COVID-19, is the world’s second largest pharmaceutical market and accounts for 20 % of the global output of APIs. With over 25 biologics and biosimilar products approved till date and close to 1,000 clinical trials, investigating a variety of biologics and biosimilars, being underway in this region, China’s biopharma market is

May 19, 2020

Neoantigen Targeted Therapies Pave the Way to Personalized Anti-cancer Therapy

By Ishita Nanda Anti-cancer, Anti-cancer Therapy, Therapies 1 Comment

Neoantigen Targeted Therapies Pave the Way to Personalized Anti-cancer Therapy There is an urgent unmet need for developing innovative and effective cancer therapeutics for the treatment of patients with late-stage and refractory cancer. Amidst the widespread initiatives to develop more targeted anti-cancer therapies, immunotherapy emerged as a highly specific and potent option to eradicate tumor

May 15, 2020

Neoantigen Targeted Therapies – A Potential Weapon in the Fight against Cancer

By Ishita Nanda Cancer, Therapies 1 Comment

Cancer – one of the most feared and dreaded diseases. It is known to be one of the leading causes of death worldwide, accounting for 0.6 million deaths in 2018, in the US alone. The World Health Organization has estimated the number of new cancer cases, reported across the globe, to rise by 70% over

May 14, 2020

Pandemic Like Never Before – Continuous Manufacturing to the Rescue

By Ankita Kashyap Contract Manufacturing, Coronavirus, COVID-19 1 Comment

The coronavirus outbreak and the drop in economy that we are facing today is unlike anything that most of us have seen in our lifetime. The pandemic has threatened the whole world to such an extent that life has come to a standstill. In fact, the initial stage of lockdown featured the fragile nature of

May 7, 2020

The Future of Manufacturing: Collaborative Robots in the Factories

By Nancy Kapila Cobots, Robots 1 Comment

The world has experienced a radical change with the advancements in technologies and systems that aid daily activities. Particularly, automation has played an important role in increasing the productivity and quality of the production process in various industries. Within the automation industry, robots have already been established; however, one of the fastest-growing segment of robotics

May 4, 2020

How can Cobots Help in Pandemic Management?

By Nancy Kapila Cobots, Coronavirus, COVID-19, Robots 1 Comment

With the new threat to humanity presented by Pandemic COVID-19, another bigger challenges for the pharmaceutical industries are bulk vaccine production in the limited time span. How will the pharma sector be going to cope with these challenges? Well, automation has always improved the quality and efficiency of the production process in the pharmaceutical industry

April 24, 2020

COVID 19 and Vaccines: How Big Will be the Impact on Prefilled Syringes Market?

By Gaurav Chaudhary Coronavirus, COVID-19, Medical Device, Vaccines 1 Comment

Coronavirus(COVID 19) is spreading around the world, with 2.6 million global active cases[TB1] . Till date, there are no approved treatments for COVID-19. However, multiple pharmaceutical companies are doing research at breakneck speed to develop therapeutics and preventive vaccines against this novel coronavirus. The pharma industry is hoping to compress the development timelines to get a

April 22, 2020

COVID-19 and Recession: How Big will be the Impact?

By Gaurav Chaudhary Coronavirus 2 Comments

In a blog posted a few weeks ago, I talked about the key strategies that the pharma companies can adopt to deal with the impact of COVID-19. The strategies were dependent on the position of the companies on the recession readiness evaluation framework (added below). Check out the blog for more details on this. Two

April 9, 2020

COVID-19 and Recession: Identifying Long-Term Growth Opportunities

By Gaurav Chaudhary Biopharmaceutical, COVID-19 0 Comments

Well before the COVID-19 pandemic, there were warning signs of an imminent US recession. The ongoing pandemic, and trade conflicts between the US. and China, and the US and Europe have just accelerated the fall of the global economy. In fact, as per the United Nations, the world economy is expected to go into recession

April 6, 2020

COVID-19: Drugwatch – 6 April 2020

By Snehasish Das COVID-19 1 Comment

To date, there are no approved treatments for COVID-19. However, the pharmaceutical industry is abuzz with activity as medical researchers strive to develop a cure, and possibly a vaccine, for the illness caused by the novel coronavirus. In this article, we have attempted to explore some of the more popular treatments / preventive measures that

April 6, 2020

Beyond COVID-19: Is the World Ready to Embrace the New Normal?

By Gaurav Chaudhary COVID-19 1 Comment

It is the first time in the history of medicine that so many scientists / researchers across the globe focused so urgently on a single disease in such a short span of time. Looking at the developments in the past few month, I really feel that COVID-19 has changed how the world does science together.

April 6, 2020

Stem Cell Therapy: A Ray of Hope to End Global Pandemic of COVID-19

By Ronit Sharma Coronavirus, Stem Cell Therapy 0 Comments

I would never have thought that a mutant flu virus could create that big panic in people at each and every corner of the world. In fact, the past few days in quarantine have really made me realize where exactly the humanity is heading. For majority of us, our lives are on a temporary hold

April 5, 2020

COVID-19: Where are we today?

By Snehasish Das Infectious Diseases 4 Comments

Comparison with other communicable diseases According to worldometers.info, as of 5 April 2020 (5:30 PM GMT), the total number of COVID-19 cases rose to over a million, with a reported mortality rate of 5%. Further, a comparison with certain other communicable disease-related deaths (Figure below) presents a worrisome situation. As of 5-April 2020, the novel

April 2, 2020

Fragment-based Drug Discovery – A Boon in Disguise to get a Breakthrough Drug Against Covid-19

By Ishita Nanda Drug Discovery 0 Comments

With over 855,000 cases and 42,000 deaths, the novel coronavirus has taken its toll on humanity. The pandemic is predicted to throw the global economy into recession, with loss of trillions of dollars. The pharmaceutical industry cannot escape the brunt of the circumstances as well. In fact, according to a survey, 95% of healthcare industry

April 2, 2020

Coronavirus: Stem Cell Contract Manufacturing Demand to Surge Rapidly

By Ishita Nanda Coronavirus, Stem Cells 1 Comment

As is the case with numerous pharmaceutical companies who have been racing to find a potential cure for the patients suffering from infection with Corornavirus, the stem cell industry has been on an outlook to identify stem cell therapies which can treat the disease and / or its symptoms. Athersys is developing a possible therapy

April 1, 2020

NHS Advises COVID-19 Related Risk Assessment of Phase I Trials

By Gaurav Chaudhary Clinical Trials 1 Comment

In a recently released statement, the NHS has advised all companies that are conducting early phase clinical trials to seek confirmation that the trials have undergone a risk assessment in relation to coronavirus (COVID-19). As per the statement, this is likely to result in the halt/termination of some of the trials. With several governments announcing

March 29, 2020

COVID-19 Impact on Cell and Gene Therapy Manufacturing Market

By Gaurav Chaudhary Cell Therapy, Gene Therapy, Vector Manufacturing 1 Comment

With close to half-million infections and the economy showing signs of the 2008 financial crisis, COVID-19 has impacted several industries. Government institutes and industry players have announced various steps to deal with the ongoing situation. In this article, we will highlight the developments in the cell and gene therapy manufacturing industry amid the ongoing COVID-19

March 29, 2020

Continuous Manufacturing: Solution to Pharmaceutical Manufacturing Industry’s COVID-19 Concerns

By Gaurav Chaudhary Contract Manufacturing, Pharmaceuticals 1 Comment

The ongoing COVID-19 crisis has put the pharmaceutical manufacturing supply chain under close scrutiny. The overdependence of the US on China and India to meet its API demand has been the talk of the town. However, with the number of infected cases in the US surpassing that of China, the focus has shifted from discussing

March 29, 2020

COVID-19 Impact on Gene Therapy Market

By Gaurav Chaudhary Gene Therapy 2 Comments

COVID-19 Impact on Continuous Manufacturing Market

In a recent press release, bluebird bio, one of the leading gene therapy developers, announced that COVID-19 has delayed the EU launch and US filing of the company’s gene therapy candidate Zynteglo (LentiGlobin). The company now expects to dose the first commercial patient with Zynteglo in Germany in the second half of 2020. Earlier, the company had

March 29, 2020

COVID-19 Vaccine: Do We Have Enough Manufacturing Capacity?

By Gaurav Chaudhary Vaccines 2 Comments

As per a recent article published in Financial Times, Sanofi has warned that Europe lacks the vaccine manufacturing capacity to cope with pandemics like the coronavirus. Roots Analysis, in a recent report, has identified more than 40 vaccines that the currently being developed against COVID-19. To know more about the vaccines under development, check out

March 29, 2020

Clinical Trials During COVID-19: Time to go Virtual

By Gaurav Chaudhary Clinical Trials 2 Comments

The ongoing COVID-19 pandemic has been nothing short of a nightmare. As the number of infected patients approaches 400,000, there is already a sense of worry looming across the industries. From disrupted supply chains to a prominent decrease in demand, the pharmaceutical industry is also facing its share of difficulties. We, at Roots Analysis, have

March 24, 2020

Contraband in the Clinical Trials -A saga of the great apes, who went on to ban the nature

By Ishita Nanda Clinical Trials, Pharmaceuticals 3 Comments

To err is human, to rectify divine, this irony perhaps holds truer for cannabis than any other domain. After using cannabis in multiple forms for at least 10,000 years, a series of events, including spread of misinformation, anti-Mexican sentiment and fear led to the ban of nature a.k.a. cannabis. The US implemented Marijuana Tax Act

March 16, 2020

Immuno-Oncology Biomarker: Benchmarking Big Pharma Activity

By Gaurav Chaudhary Diagnostics, Oncology 1 Comment

Is genomics revolution all fun and games?

Over the past few years, therapeutic advancements in conventional treatment paradigms have led to an increase in survival among cancer patients. Recent developments in the field of immuno-oncology, such as the introduction of several cancer vaccines, adoptive T-cell therapies, and checkpoint inhibition therapies, have demonstrated significant potential, and some of the aforementioned therapies have already

March 15, 2020

Cell Therapy Manufacturing: Here are the Key Innovations

By Gaurav Chaudhary Cell Therapies, Cell Therapy, Gene Therapy 2 Comments

Last week, during our weekly industry update sessions, our prime focus was to understand the recent innovations in the field of cell therapy manufacturing. We were also looking out for players that are driving these innovations. To start with, the first news that caught our attention was Novartis’ decision to sidestep Europe travel ban to

March 13, 2020

Nurix betters Kymera: The Targeted Protein Degradation War Is Heating Up

By Gaurav Chaudhary Pharmaceuticals 1 Comment

It is not very common to hear venture capital firms back competitors in the same week. It happened yesterday with Nurix announcing a USD 120 million backing yesterday, immediately after Kymera had grabbed an almost similar amount earlier this week. This does tell us something about the field of Targeted Protein Degradation! Read on. How

March 12, 2020

Targeted Protein Degradation and the Rise of Kymera Therapeutics

By Gaurav Chaudhary Pharmaceuticals 1 Comment

Targeted protein degradation (TPD), as a mechanism to target previously untreatable conditions, was one of the key highlights of the year 2019. In an article published late last year, we discussed, in detail, the epic rise in the popularity of TPD. What is targeted protein degradation? Targeted protein degradation is an emerging modality that allows

March 12, 2020

Microbiome Contract Manufacturing: Time to Push the Increase Capacity Button

By Gaurav Chaudhary Contract Manufacturing, Microbiology 1 Comment

The interest in the trillions of microbiome present in the human body has attracted a lot of research effort in the microbiome domain. The first such effort at a large scale was The Human Microbiome Project, conducted by the National Institutes of Health in the United States, which characterized the microbial communities at five major

March 11, 2020

Cell Therapy and The Rise of Novel Technologies

By Gaurav Chaudhary Cell Therapies, Cell Therapy, Contract Manufacturing, Gene Therapy, Natural Killer Cells 2 Comments

Roots Analysis has actively tracked the developments in the field of cell therapy and gene therapies. The team has focused on identifying the key challenges that are hampering the growth of these revolutionary therapies. To identify the challenges, the team has interviewed several stakeholders involved in cell therapy development and manufacturing. In addition, a recent

March 9, 2020

Coronavirus: The World Must Unite In Its Fight

By Gaurav Chaudhary Biologics, Vaccines 1 Comment

A lot has happened. And that too in a short span of time. A few weeks ago, everyone outside China was worried about the quarantined cruise ships. No one at that stage would have thought that, just in a few days, the virus may be knocking at the doorsteps. Now there is fear and it

March 6, 2020

ADCs: The Excitement Continues to Build

By Gaurav Chaudhary Biologics, Drug Discovery 1 Comment

So, another round of the World ADCs just concluded. With a stellar line up that included Alain Beck from Pierre Fabre, Thorsten Sperber from Immunomedics, Nicholas Choong form Seattle Genetics, Rakesh Dixit from BioNavigen, Trevor Hallam from Sutro Bio and many other eminent personalities, the event did live up to its expectations. ADCs continue to

February 14, 2020

Is genomics revolution all fun and games? How blockchain can calm data security nerves!

By Gaurav Chaudhary Diagnostics, Drug Discovery, Genomics 2 Comments

Have you had your genomics sequenced? If you asked this question a few years ago, people would have thought you were crazy. However, today, genetic tests are up for sale in supermarkets! Fifteen years ago, the first ever Human Genome Project was carried out, which took more than 13 years to complete. This (Human Genome

February 4, 2020

Catalent’s Shopping List: Hinting Towards a One-Stop Cell & Gene Therapy CMO in Making

By Gaurav Chaudhary Cell Therapy, Gene Therapy 3 Comments

There appear to be no Monday blues for Catalent as the company announces the acquisition of MaSTherCell Global, a technology-focused cell and gene therapy contract development and manufacturing organization. Following its last year’s acquisition of Paragon Bioservices (a leading viral vector developer), Catalent’s recent acquisition has extended the company’s leadership in this already crowded space.

January 3, 2020

Cell and Gene Therapy Manufacturing: Rising Demand Forces Companies to Look Beyond Viral Vectors

By Gaurav Chaudhary Cell Therapies 2 Comments

The rise in the popularity of cell and Gene Therapy has been widely talked about in recent years. The rise in this popularity has come with its own challenges, a number of which were identified in a recent report by Root Analysis. The challenges vary from the high cost of manufacturing to low capacity. In

January 2, 2020

Vector Manufacturing Market: Opinion Leaders Highlight Key Concerns

By Gaurav Chaudhary Vector Manufacturing 3 Comments

The growing pipeline of cell and gene therapies has led to an increase in demand for high-quality gene delivery vehicles and, therefore, has created significant opportunities for companies with expertise in manufacturing viral and non-viral vectors. In an article published last year, I discussed the growing cell and gene therapy market and how it has

January 1, 2020

CMO, CMO Everywhere, Not a Single One That Fits: The Reality of Biopharma Contract Manufacturing Market

By Gaurav Chaudhary Biopharmaceutical 2 Comments

I was recently involved in a discussion with the global outsourcing manager of one of the big pharma companies. The premise of the discussion was around the criteria that big Biopharma Contract players follow for choosing a supplier for their products. One key question that came up in the discussion was whether one-stop-shops are really

January 1, 2020

A Pizza Hut Prescription for Gene Therapy Companies

By Gaurav Chaudhary Gene Therapy 2 Comments

As we enter 2020, one drug class that is set to take-off is gene therapy. With three approvals (Zolgensma® (US), Zynteglo™ (Europe) and Beperminogene Perplasmid (Japan), 2019 was a break out year for gene therapy developers. The $16 billion-plus investment by various investors finally seems to be paying off as we enter 2020 with a

December 28, 2019

Growth Drivers and Roadblocks in Targeted Protein Degradation Market

By Gaurav Chaudhary Degradation Market 2 Comments

Growth Drivers and Roadblocks in Protein Degradation

In a recent article, I discussed the rise of protein degradation therapeutics and the surge in big pharma interest in this emerging space. With more than 3,600 tweets posted over the last three years to over 5,000 articles published over the last decade, the concept of protein degradation has got the right people talking. In

December 27, 2019

DNA Encoded Libraries: Big Pharma Interest Rises as Technology Proves Benefits

By Gaurav Chaudhary DNA Encoded 3 Comments

When a big pharma agrees to spend millions in acquiring a drug discovery company, the world is bound to take note. The same happened earlier this year – the acquisition of Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) was a piece of big news in the drug discovery world, validating the potential of DNA

November 12, 2019

Evolution of Cancer Diagnostics: Rise of Novel Non-Invasive Methods

By Gaurav Chaudhary Cancer 0 Comments

Cancer diagnosis, today, employs a mix of invasive and non-invasive strategies. Invasive cancer diagnostic methods are generally expensive and uncomfortable. Biopsies have been the gold standard to determine the clinicopathological characteristics of cancer tissues for many years. The procedure is very uncomfortable and painful for patients and in many cases, the results are known to

November 12, 2019

CAR-T Pipeline Update: Autolus Therapeutics Presents Preclinical Data on AUT06NG

By Gaurav Chaudhary Cell Therapies 0 Comments

Autolus Therapeutics, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, presented pre-clinical data on AUTO6NG, the company’s next-generation GD2-targeting CAR (chimeric antigen receptor) T cell therapy, at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). What did the results highlight: The results demonstrated the utility

November 11, 2019

Microbiome Research Update: New Study Uncovers Role of Bacteria in Bowel Cancer

By Gaurav Chaudhary Microbiome Research 0 Comments

Dr. Kaitlin, from the University of Bristol, speaking at the 2019 NCRI Cancer Conference, confirmed that they have discovered evidence of the presence of an unclassified type of bacteria from the bacterial group named ‘Bacteroidales’ increased the chances of bowel cancer by 2 to 15 percent. The researchers employed the technique known as Mendelian randomization to

November 11, 2019

New Research in ALS – Mitoautophagy Responsible for Development of Early Stages of Neurodegeneration

By Gaurav Chaudhary Neurodegeneration 0 Comments

Researchers at Northwestern Medicine have discovered a new phenomenon in the brain that could explain the development of early stages of neurodegeneration seen in diseases such as ALS, which affects voluntary muscle movement such as walking and talking Mitoautophagy. What is the discovery: The researchers have invented a new term to describe the discovery: Mitoautophagy,

November 9, 2019

FDA Approves Celgene’s REBLOZYL® for the Treatment of Anemia

By Gaurav Chaudhary Celgene's REBLOZYL 0 Comments

The U.S. Food and Drug Administration (FDA) has approved Celgene’s REBLOZYL® (luspatercept-aamt) for the treatment of anemia in adult patients with beta-thalassemia who require regular red blood cell (RBC) transfusions. What is Beta-thalassemia: Beta-thalassemia is a blood disorder that reduces the body’s production of hemoglobin. Low levels of hemoglobin lead to a shortage of mature red blood cells and a lack of oxygen in

November 9, 2019

CAR-T Pipeline Update: Celgene posts pivotal data ahead of FDA filing

By Gaurav Chaudhary Cell Therapies, Cell Therapy 0 Comments

Celgene has recently published positive data from a pivotal trial (NCT02631044) of its CAR-T therapy. As per the reports, the data look competitive against Gilead’s Yescarta and Novartis’ Kymriah, leading analysts to predict Celgene will win FDA approval next year. This is a big news for the overall CAR-T pipeline. As per the reported data, the

November 8, 2019

New Real-World Data Unveiled at ACAAI Indicates Comparable Clinical Practice Logistics to Implement Oral Immunotherapy and Environmental Allergy Shots

By Gaurav Chaudhary Clinical Practice 0 Comments

In a recent press release by Aimmune Therapeutics, the company reported that the Clinical Practice logistical needs for implementing oral immunotherapy (OIT) for food allergies, such as peanut allergy, into clinical practice are comparable to those for subcutaneous immunotherapy (SCIT) for environmental allergies. These data were presented at the American College of Asthma, Allergy and Immunology

November 8, 2019

CRISPR-edited Immune Cells Prove Safe in Small Cancer Study

By Gaurav Chaudhary Genomics 0 Comments

At the American Society of Hematology (ASH) annual meeting in Orlando, the team, led by the Abramson Cancer Center of the University of Pennsylvania, will discuss two multiple myeloma patients and one sarcoma patient who is participating in a trial, which is also supported by Tmunity Therapeutics (a company that recently raised $75 million in

November 8, 2019

Party Like Celebrities: American Gene Technologies Hosts a Red Carpet Event to Celebrate IND Submission

By Gaurav Chaudhary Gene Technologies 0 Comments

On November 6, 2018, American Gene Technologies (AGT) announced that it will host a red carpet event to celebrate a significant milestone in the company’s 11-year history of scientific research in cell and gene therapy. Last month, the company successfully submitted its Investigational New Drug (IND) application to the Food & Drug Administration (FDA) to

November 8, 2019

T-Cell Therapies Funding Update: Tmunity Raises $75 Million in Series B Funding

By Gaurav Chaudhary T-Cell Therapies 0 Comments

On 31st October 2019, Tmunity Therapeutics, a private biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell Therapies, announced the closing of $75 million Series B financing. Who were the key investors: The financing was led by Andreessen Horowitz (also known as “a16z”). Joining the Series B

November 8, 2019

Avantgen Enters a Strategic Collaboration Agreement for its NK Cell Engager Technology

By Gaurav Chaudhary Natural Killer Cells 0 Comments

On 7 November 2019, AvantGen, a biotechnology company with its array of technology platforms for antibody discovery, optimization, and novel NK cell engager generation, announced a strategic agreement with an undisclosed biopharmaceutical company for the purpose of generating multiple novel bi-specific NK cell engaging therapeutic antibody product candidates. Under the terms of the agreement, AvantGen

November 4, 2019

CARsgen anti-BCMA CAR T Therapy Receives RMAT Designation

By Gaurav Chaudhary Cell Therapy 0 Comments

On 28 October 2019, CARsgen Therapeutics, a clinical-stage biopharma company, announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational CT053 CAR-T cell therapy. What is CT-053: CT053 is a fully human anti-BCMA (B Cell Maturation Antigen) autologous chimeric antigen receptor (CAR) T Cell therapy for the treatment of relapsed and/or refractory multiple

November 3, 2019

61% of the Genome Editing Service Providers are based in North America

By Gaurav Chaudhary Genome Editing 0 Comments

61% of the CRISPR based genome editing service providers are based in North America.

The rising demand for genome editing services has resulted in the rise of several players in the last few years. Around 61% of the companies that offer these services are based in North America. To get more free insights about the genome editing services market, check out the report here.

November 3, 2019

Cell Line Engineering is the Most Common Service Offered by CRISPR-Based Genome Editing Companies

By Gaurav Chaudhary Uncategorized 0 Comments

Infographic: Genome Editing Services Market By Services. Close to 31% of the CRISPR based genome editing service providers offer services for cell line engineering

As per a recent market report by Roots Analysis, cell line engineering is the most popular service, provided by close to 31% of the CRISPR based genome editing service providers. To get additional free insights about the genome editing services market, check out the report here.

November 3, 2019

Genome Editing Services Market Snapshot

By Gaurav Chaudhary Genomics 0 Comments

Genome editing services market comprises of close to 80 players that claim to offer CRISPR-based genome editing services

The rising demand for genome editing services has resulted in the rise of several players with a wide range of capabilities. Currently, there are close to 80 players that claim to offer CRISPR based genome diting services. To get more insights about the market, check out the detailed report here.

November 3, 2019

Medical Device Contract Manufacturing Market Size

By Gaurav Chaudhary Medical Device 0 Comments

Infographic: Medical Device Contract manufacturing market is expected to reach $126 billion at a CAGR of 8%

More than 100 medical devices were approved by the FDA in 2018, while several are currently being evaluated across more than 9,500 (active) clinical trials, worldwide. Further, the increase in the aging population, coupled with a rise in the prevalence of chronic disorders, are likely to drive the demand for medical devices. Therefore, in order

November 3, 2019

Experts Highlight Unmet Needs in T-Cell Therapies Market

By Gaurav Chaudhary T-Cell Therapies 0 Comments

Expert Opinion on T-Cell Therapies Market

The CAR-T therapies market is projected to reach USD 11 Billion by 2030, growing at an annualized rate of 31%. Check out more insights about the overall T-cell therapies market, here.

November 3, 2019

More than 50 Large Volume Wearable Injectors are Available / Under Development

By Gaurav Chaudhary Autoinjectors 0 Comments

Infographic: Large Volume Wearable Injectors Market

Over time, both drug developers and medical device Injectors manufacturers, have entered into strategic alliances to combine their respective expertise and develop appropriate drug-device combination products. Presently, multiple such combinations, facilitating easy delivery of both insulin and non-insulin drugs, in large volumes, are either already available in the market or under development. Check out more

November 3, 2019

Auristatin has Emerged as Most Popular Payload in ADC Clinical Pipeline

By Gaurav Chaudhary Clinical Pipeline 0 Comments

Auristatin payload containing antibody drug conjugates occupy close to 60% of the ADC clinical pipeline

For more free insights about the market, check out the detailed report here.

November 3, 2019

Antibody Drug Conjugates Pipeline

By Gaurav Chaudhary Antibody Drug 0 Comments

More than 240 antibody drug conjugates are current under development

For more free insights, check out the detailed report here.

November 3, 2019

Stem Cell Therapy Contract Manufacturing Market

By Gaurav Chaudhary Stem Cell Therapy 0 Comments

Check the detailed report here.

November 2, 2019

ADCs Pipeline Update: Avacta Partners with ADC Therapeutics

By Gaurav Chaudhary ADCs Pipeline 0 Comments

On November 1, 2019, Avacta Group and ADC Therapeutics have announced a collaboration agreement for the development of novel drug candidates. What is the objective of the collaboration: The partnership will aim at the development of drugs combining ADC Therapeutics’ pyrrolobenzodiazepine-based cytotoxic warheads with Avacta’s Affimer targeting platform. What are the financial terms of the agreement: The detailed

November 2, 2019

ADCs Pipeline Update: Daiichi Sankyo Initiates Clinical Trial

By Gaurav Chaudhary ADCs Pipeline 0 Comments

On October 31, 2019, Daiichi Sankyo and Sarah Cannon Research Institute announced the dosing of the first patient in a first-in-human phase 1/2 study (NCT04145622) evaluating DS-7300. What is DS-7300: DS-7300 is an investigational B7-H3 targeting antibody-drug conjugate (ADC). What is B7-H3: It is a Type I transmembrane protein belonging to the B7 family, which includes immune checkpoint

November 1, 2019

The Treasure Hunt for Novel Biomarkers and Rise of TMB

By Gaurav Chaudhary Diagnostics 0 Comments

Over the years, several cancer-related biomarkers have been identified, which can be used to predict response to certain types of immunotherapy drugs. However, due to the inherent complexity of the immune microenvironment and differences in the genomic makeup of individual patients, most of these biomarkers have been proven to be insufficient in predicting how a

October 30, 2019

ADCs Pipeline Update: Sutro Biopharma Presents Encouraging Data in Patients with Advanced Ovarian Cancer

By Gaurav Chaudhary ADCs Pipeline 0 Comments

Sutro Biopharma, a California based, clinical-stage company, announced initial safety data in ovarian cancer patients from its ongoing phase I study (NCT03748186) of STRO-002. The drug is a folate receptor alpha (FolRα)-targeting antibody-drug conjugate (ADC) and potent anti-tumor activity in preclinical endometrial cancer patient-derived xenograft (PDX) models. The data are being presented at the AACR-NCI-EORTC Molecular Targets

October 30, 2019

ADCs Pipeline Update: Femtogenix Presents Novel Data on ADCs Containing Reduced Potency Payloads

By Gaurav Chaudhary ADCs Pipeline 0 Comments

Femtogenix, a UK based biotechnology company developing the next generation of DNA-interactive Antibody Drug Conjugate (ADC) payloads, announced data demonstrating the potent efficacy and favorable toxicity profile of a reduced potency analog from its Pyridinobenzodiazepine (PDD) ADC payload platform in solid tumor models. The presented data demonstrated that Femtogenix’s reduced potency payload has a favorable

October 25, 2019

Antibody Drug Conjugates Market Update: Ambrx and NovoCodex Collaborate

By Gaurav Chaudhary Antibody Drug 0 Comments

Ambrx and NovoCodex Biopharmaceuticals announced that they have formed a second collaboration to develop and commercialize Ambrx’s internally developed site-specific antibody drug conjugates (ADCs). What is the focus of the agreement: Under the agreement, Ambrx and NovoCodex will join forces to continue the development of ARX305, an Ambrx enabled ADC for the treatment of CD70

October 25, 2019

Cell Therapy Manufacturing Market Update: Compal and University to set up GTP lab

By Gaurav Chaudhary Cell Therapy 0 Comments

The Compal Group’s Raypal Biomedical and Kaohsiung Medical University Chung-Ho Memorial Hospital on October 22 signed an MoU to jointly set up a GTP (good tissue practice) cellular laboratory in Kaohsiung City, southern Taiwan. What are the key capabilities of Raypal: Founded in 2016, Raypal specializes in R&D of immunocyte and immunotherapy, stem cell and

October 25, 2019

Cell Therapy Pipeline Update: Talaris Therapeutics Announces Initiation of Phase 3 Clinical Trial

By Gaurav Chaudhary Cell Therapy 0 Comments

Talaris Therapeutics, a late-clinical stage biotechnology company based in Boston, MA and Louisville, KY, announced the initiation of FREEDOM-1 (NCT03995901), the company’s Phase 3 clinical trial of FCR001 in living donor kidney transplant (LDKT) recipients. What is the objective of the trial: This pivotal trial will evaluate the safety and efficacy of a single dose of FCR001,

October 25, 2019

Gene Therapy Pipeline Update: Orchard Therapeutics Presents Data on Metachromatic Leukodystrophy

By Gaurav Chaudhary Gene Therapy 0 Comments

Orchard Therapeutics, a commercial-stage biopharmaceutical company, announced initial results from a clinical trial (NCT03392987) with a cryopreserved formulation of OTL-200, gene therapy in development for the treatment of metachromatic leukodystrophy (MLD). Get the details of the results here. What is OTL-200: OTL-200 is autologous CD34+ cells transduced with a lentiviral vector containing human arylsulfatase A (ARSA) complementary deoxyribonucleic

October 25, 2019

Cell Therapy Market Update: MaxCyte Advances Phase I Clinical Trial of Lead mRNA-based Cell Therapy

By Gaurav Chaudhary Cell Therapy 1 Comment

MaxCyte, the global Cell Therapy, and life sciences company, announced the initiation of dosing in the third cohort of patients of MaxCyte’s Phase I clinical trial (NCT03608618) with the next higher cell dose of MCY-M11. The dose-escalation trial is evaluating the safety and tolerability, as well as preliminary efficacy, of MCY-M11 administered intraperitoneally across a series

October 25, 2019

Genome Editing Market Update: Intellia Therapeutics Presents Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy

By Gaurav Chaudhary Therapeutics 1 Comment

Intellia Therapeutics, one of the leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology is presenting one oral presentation and four poster presentations at the 27th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) meeting taking place October 22-25, 2019, in Barcelona, Spain. Get a complete

October 25, 2019

Gene Therapy Pipeline Update: Adverum Biotechnologies Doses First Patient for Wet AMD

By Gaurav Chaudhary Gene Therapy 1 Comment

Adverum Biotechnologies, a clinical-stage gene therapy company developing drugs to teated rare ocular diseases, announced that the first patient was dosed in the third cohort (n=9) of the ongoing OPTIC phase 1 clinical trial (NCT03748784) for ADVM-022 for the treatment of neovascular or wet age-related macular degeneration (wet AMD). What is ADVM-022: ADVM-022 utilizes a propriety

October 25, 2019

Gene Therapy Pipeline Update: AVROBIO Receives Orphan-Drug Designation

By Gaurav Chaudhary Gene Therapy 1 Comment

AVROBIO, a US-based company, developing lentiviral-based gene therapies, has announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for the Company’s investigational gene therapy, AVR-RD-02, for the treatment of Gaucher disease. What is AVR-RD-02: AVR-RD-02 consists of the patient’s own hematopoietic stem cells, genetically modified to express glucocerebrosidase (GCase), the enzyme that is deficient

October 25, 2019

Cell Therapy Manufacturing Update: United Therapeutics Receives Permit

By Gaurav Chaudhary Cell Therapies, Cell Therapy, Contract Manufacturing, Stem Cells 0 Comments

As per recent news coverage, United Therapeutics has received a permit for $9.5 million build-out of its cell therapy facility on the second floor of Mayo Clinic’s Discovery and Innovation Building. What is the area of the facility: The facility will have a total of 21,843-square-foot space. What are the capabilities at the facility: The facility will house

October 24, 2019

Gene Therapy Funding Update: With a Promise of $100 Million in Funding, US Government Bets Big on Gene Therapy

By Gaurav Chaudhary Gene Therapy 1 Comment

In a recent press announcement, The U.S. National Institutes of Health (NIH) has agreed to invest in the development of Gene Therapy in an attempt to cure HIV and sickle cell diseases. The program, for which NIH will partner with The Bill & Melinda Gates Foundation, will involve funding of $100 million each over the next

October 24, 2019

Cell and Gene Therapy Technology Update: ReNeuron Presents Positive Data

By Gaurav Chaudhary Cell Therapies, Cell Therapy, Gene Therapy 1 Comment

ReNeuron, the UK based, clinical-stage stem cell therapeutics company, announced that new data relating to its CTX stem cell platform will be presented today at the 27th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT). Dr. Steve Pells, Principal Investigator at ReNeuron, will present new data showing the phenotypic stability and scalability

October 22, 2019

Gene Therapy Pipeline Update: AGTC Presents Promising Data of its AAV Vectors for Ocular Gene Therapy

By Gaurav Chaudhary Cell Therapy, Gene Therapy 1 Comment

Applied Genetic Technologies Corporation (AGTC), a clinical-stage biotechnology company, developing transformational genetic therapies for patients suffering from rare and debilitating diseases, announced new data from non-clinical studies evaluating the effect of pre-existing anti-AAV antibodies on the transduction and expression efficiency of AAV vectors. According to the company’s CSO, Preexisting immunity to AAV remains a challenge for

October 22, 2019

Gene Therapy Pipeline Update: Rocket Pharmaceuticals Receives IND Clearance for Gene Therapy for Pyruvate Kinase Deficiency

By Gaurav Chaudhary Gene Therapy 1 Comment

Rocket Pharmaceuticals, a New York-based, clinical-stage company, developing first-in-class gene therapies for rare and devastating inherited diseases announced clearance of Investigational New Drug (IND) by the FDA for RP-L301 gene therapy. RP-L301 is a lentiviral vector (LVV)-based gene therapy for the treatment of Pyruvate Kinase Deficiency (PKD), a genetic rare disease. Last month, the company received

October 22, 2019

Gene Therapy Pipeline Update: Homology Medicines Presents Data Demonstrating Preclinical Proof-of-Concept

By Gaurav Chaudhary Gene Therapy 1 Comment

Homology Medicines, a company using proprietary gene editing and gene therapy platform announced the presentation of preclinical data supporting its investigational gene therapy programs for the treatment of metachromatic leukodystrophy (MLD) and phenylketonuria (PKU) at the American Society of Human Genetics (ASHG) 2019 Meeting. The presented preclinical data showed the results from studies conducted in

October 22, 2019

Alzheimer’s Pipeline Update: Biogen Takes a U-Turn on Failed Drug; Approval in Sight

By Gaurav Chaudhary Alzheimer's Pipeline 1 Comment

In one of the most drastic shifts in fortune in the pharmaceutical industry, Biogen has decided to submit its previously failed Alzheimer’s drug for approval. According to the company, The Phase 3 EMERGE (NCT02484547) study met its primary endpoint showing a significant reduction in clinical decline, and Biogen believes that results from a subset of patients

October 22, 2019

Cell Therapy Manufacturing Update: Merck Becomes the First to Introduce Acoustic Technology

By Gaurav Chaudhary Cell Therapy 1 Comment

With its acquisition of FloDesign Sonics earlier this month, Merck/MilliporeSigma has become the first company to introduce acoustic technology in cell therapy manufacturing. The acquisition of FloDesign Sonics is a strategic fit for Merck, strengthening its ability alongside to manufacture cell-based therapies for patients. What is Acoustic Cell Processing: Acoustic cell processing is a disruptive technology that allows

October 22, 2019

Plasmid DNA Manufacturing Market Update: Cytovance®Introduces Integrated Single-Use Platform

By Gaurav Chaudhary DNA Manufacturing 1 Comment

In the ongoing shift of biologics manufacturers to single-use systems, Cytovance®, a leading biopharmaceutical CDMO, announced the addition of an integrated single-use platform for the manufacturing of plasmid DNA (pDNA) at their facilities in Oklahoma City, OK. According to the company, two grades are available (Critical Reagent Grade™, CGMP-grade) in lot sizes from 1g to 50g,

October 22, 2019

Gene Therapy Funding Update: Exegenesis Bio raises $10 Million led by K2 Venture Partners

By Gaurav Chaudhary Gene Therapy 0 Comments

The gene therapy company, Exegenesis Bio has become one of the recent players to receive funding in the therapy space. According to a media statement, the company has completed fundraising of over 70 million yuan ($10 million), led by K2 Venture Partners and joined by Kaitai Capital and Legend Star. The company was founded by

October 22, 2019

Gene Therapy Market Update: Researchers Deliver a Cure for Epidermolysis Bullosa (EB)

By Gaurav Chaudhary Gene Therapy 1 Comment

In a recent news update, a team of Irish gene therapy researchers announced a breakthrough in the search for a cure for one of the worst strands of the incredibly painful skin disease, EB (epidermolysis bullosa). According to the researchers, the incredibly painful genetic condition, which affects approximately 300 people in Ireland, is caused by a

October 21, 2019

Gene Therapy Market: A Strong Pipeline with $12 Billion Opportunity by 2030

By Gaurav Chaudhary Gene Therapy 1 Comment

From being a thing of science fiction to topping the priority list of every big pharma player, gene therapies have come a long way. With multiple approved products, the field of gene therapies has gained substantial momentum over the last couple of decades. The growing burden of genetic disorders and the rising evidence of gene

October 21, 2019

Technological Evolution of ADC Conjugation Platforms

By Gaurav Chaudhary ADC Conjugation 1 Comment

Last week, I wrote an article on the key innovators in ADC therapeutics space,Technological highlighting the key winners at the 6th World ADC Awards. One of the winners, that has really impressed several drug developers in this space, is Zymeworks. The company has its proprietary conjugation Technological platform, ZymeLink™, which offers site-specificity and customization of

October 21, 2019

Gene Therapy Market: Big Pharma Bets Big

By Gaurav Chaudhary Gene Therapy 0 Comments

Last week, I came across an interesting article by Andrew Dunn titled Sanofi investing in gene therapy as R&D focus turns toward rare disease. The article caught my attention because in June, this year, Sanofi scaled back its four-year-old gene therapy alliance with Voyager Therapeutics, for the second time. If we just look at the news titles,

October 18, 2019

ADC Therapeutics Market: 6th World ADC Awards Unfold Key Innovators

By Gaurav Chaudhary ADC Therapeutics 1 Comment

Last week, the eyes of all the key stakeholders in the Antibody Drug Conjugates (ADCs) space were on the developments happening in San Diego, California, at the 6th World ADC Awards. The awards were meant to recognize the companies that are driving innovation in the field of ADCs Therapeutics. With six approved and marketed drugs,

October 17, 2019

10 Key Facts About Antibody Drug Conjugates Market

By Gaurav Chaudhary Antibody Drug 0 Comments

For more insights about the market, please click here.

October 15, 2019

10 Key Facts About Gene Therapies Market

By Gaurav Chaudhary Gene Therapies 0 Comments

For key insights on the market click here

October 14, 2019

T-Cell Immunotherapies Market: KOL Interviews Highlight Key Trends

By Gaurav Chaudhary T-Cell Immunotherapies 1 Comment

T-Cell immunotherapies have gained a lot of traction in recent years. With a plethora of clinical evidence and billions of dollars in investment, calling T-cell therapies as the next big thing might not be incorrect. As per the recent estimates, this space is likely to grow to USD 26 billion by 2030, at a CAGR

October 14, 2019

Hunt for Novel Cancer Treatment Options and Rise of T-Cell Immunotherapies

By Gaurav Chaudhary Novel Cancer 1 Comment

Novel Cancer is known to be one of the leading causes of death worldwide, accounting for more than 600,000 deaths in 2018 in the US alone. As per the recent reports by, the World Health Organization (WHO), the number of new cancer cases globally is expected to rise by 70% in the coming 20 years. Despite

October 12, 2019

Super Generics Market: The Untapped Gold Mine

By Gaurav Chaudhary Generics Market 0 Comments

The Super Generics industry has enjoyed a remarkable run over the past two decades. The vast healthcare cost-saving potential of these therapies has accelerated their adoption and proven the immense potential that generics have to reach wider patient segments. The problems arrive: While the generics market is highly attractive, the increasing competition in this domain

October 10, 2019

Synthetic Lethality: Rising Interest from Funding Agencies

By Gaurav Chaudhary Synthetic Lethality 0 Comments

After the immense success of PARP inhibitors at ESMO 2019, synthetic lethality has become the talk of the town. From industry analysts to healthcare researchers, everyone is now interested in this emerging space. In this article, we will look at the financial backing that this domain has received over the last few years and also

October 10, 2019

Growing Cell and Gene Therapy Market: Vector Manufacturers Make Merry

By Gaurav Chaudhary Cell Therapies, Cell Therapy, Contract Manufacturing, Gene Therapy 0 Comments

Cell and Gene Therapy are the new entrants in the pharma Superstar Club. They are selling tickets faster than a Queen’s concert in the 1980s. In fact, as per the Alliance of Regenerative Medicine’s recent findings, there has been more than 75% year on year increment in funding to support the development of various cell and gene therapies.

October 9, 2019

Synthetic Lethality Market: Riding on the ESMO 2019 Success of PARP Inhibitors

By Gaurav Chaudhary Synthetic Lethality 0 Comments

After a strong showdown at ESMO 2019, both GSK and AstraZeneca have reignited the fight of small molecule anti-cancer drugs against the industry’s brawny immunotherapy push. Leading this fight is poly(ADP-ribose) polymerase (PARP) inhibitor, one of the leading synthetic lethality targets. These better than expected results at ESMO further validate the potential of synthetic lethality

August 7, 2019

Mitochondrial Disease Therapies: Unlocking Treatment for Orphan Diseases

By Arun Gupta Mitochondrial Disease 0 Comments

In the US, mitochondrial diseases are known to annually affect 1 in 5,000 individuals. It is also estimated that 1,000-4,000 children are born with a mitochondrial disease every year, in the same region. Primary mitochondrial diseases are usually difficult to diagnose. Such clinical conditions are rare and are known to affect multiple parts of the

July 18, 2019

Abuse Deterrent Formulation Technologies: Combating Prescription Drug Abuse

By Arun Gupta Abuse Deterrence, Pharmaceuticals 0 Comments

Although the healthcare industry relies on the patient to take medications responsibly; in 2017, close to 18 million individuals were reported to have misused prescription drugs, in the US. In fact, data from a National Survey on Drug Use and Health conducted in the same year, showed that an estimated 2 million Americans misused prescription

July 17, 2019

Natural Killer Cell Therapies: Pipeline Review

By Arun Gupta Cell Therapy, Natural Killer Cells 0 Comments

Natural killer (NK) Cell Therapies , or killer (K) cells, represent an important subset of cellular mediators of the innate immune system. These cells are known to be instrumental in containing viral infections and regulating tumor development, while the adaptive immune system generates an antigen-specific response. Several studies have demonstrated the various benefits of NK

July 12, 2019

Vaccine Contract Manufacturing: Current Landscape and Future Potential

By Arun Gupta Contract Manufacturing, Vaccines 0 Comments

The global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025. According to the WHO, the global vaccination rate is nearly 85%, demonstrating the high clinical demand for vaccines. In addition to meeting the growing demand for vaccines, the developers of these pharmacological interventions are also plagued by high costs of

July 12, 2019

T-Cell Immunotherapies: The Goldrush Continues

By Arun Gupta Cell Therapy, Therapeutics 0 Comments

The cancer therapeutics market is considered to be one of the most active segments within the pharmaceutical industry. In the past five years, the USFDA has approved more than 100 drugs for the treatment of different types of cancer. According to the International Agency for Research on Cancer (IARC), close to 17 million new cases

May 30, 2019

Medical Devices: The Growing Opportunities for CMOs

By Arun Gupta Medical Devices and Technology 0 Comments

In 2020, the global medical devices market is estimated to reach a net worth of approximately USD 430 billion. However, most developers lack adequate resources and the necessary expertise to manufacture medical devices and related components. Given the demand for medical devices, the opportunity for CMOs with expertise in medical devices is steadily rising. It

May 28, 2019

Neoantigen Targeted Therapies: Mapping the Future Growth Potential

By Arun Gupta Oncology 0 Comments

The World Health Organization has estimated the number of new cancer cases, reported across the globe, to rise by 70% over the next 20 years. Conventional treatment options, such as chemotherapy, surgery and radiation therapy, continue to demonstrate limited efficacy in late-stage cancers. Recent developments in genomic analysis and advances in bioinformatics have enabled the

May 16, 2019

Biologics Fill / Finish Services: Current Landscape, Growth Opportunities and Future Market Outlook

By Arun Gupta Biologics 0 Comments

According to a recent CDMO survey, about 54% respondents claimed to have collaborated with a contract service provider for clinical and commercial-scale product development projects. Specifically, fill / finish is the final step in the production process and is considered among the most crucial stages of drug product manufacturing. Biologic drug products require special procedures

May 9, 2019

Elastomeric Closures for Parenteral Containers: Current Market Landscape and Future Growth Opportunities

By Arun Gupta Pharmaceutical Packaging 0 Comments

The use of elastomeric materials, along with various types of coatings (such as FluoroTec® and Teflon®) have emerged as a promising alternative to conventional, non-coated closures used for primary packaging containers, which were prone to leaching and shedding of particulate contaminants. The advantages of using elastomeric materials in manufacturing container closures are many, including low

April 30, 2019

Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing

By Arun Gupta Cancer 0 Comments

Advances in biotechnology have enabled the development of several high throughput tools, which have led to the establishment of better biomarkers based on genome / exome profiles. Novel biomarkers, such as tumour mutation burden (TMB), microsatellite instability (MSI) / mismatch repair (MMR) deficiency, tumour infiltrating lymphocytes (TILs) and certain others, are presently being investigated across

April 29, 2019

Novel Clinical Trial Service Providers: Focus on RWD, Virtual Trials, Adaptive, Umbrella and Basket Designs

By Arun Gupta Clinical Trials 1 Comment

Studies suggest that each prescription drug requires around 10 years and over USD 2.5 billion in working capital before it reaches the market. Further, it is estimated that, in the US, 40% of the pharma industry’s R&D budget is spent solely on conducting clinical trials. Estimates suggest that nearly 85% of Novel Clinical trials fail

April 25, 2019

Depressive Disorders: Pipeline Review, Developer Landscape and Competitive Insights

By Arun Gupta Depressive Disorders 0 Comments

It has been estimated that over 300 million people (considering all age groups) suffer from depression worldwide. Depressive disorders are estimated to be responsible for an economic burden of up to USD 210 billion per year in the US. Since the 1950s, around 30 branded drugs and more than 150 generic products have been approved

April 24, 2019

Companion Diagnostics: The Road Ahead for Personalized Therapies

By Arun Gupta Diagnostics 0 Comments

It is estimated that nearly 50% of prescribed drugs / therapies fail to show adequate clinical benefits. It is also worth highlighting that companion diagnostic guided drug development efforts have been estimated to help reduce clinical trial costs by almost 60%. Since the approval of the HercepTest (in 1998) for identifying patients for treatment with

April 2, 2019

Biopharmaceutical Contract Manufacturing: Transforming Promise into Reality

By Arun Gupta Biopharmaceutical 0 Comments

Over the years, the biopharmaceutical market has grown into a prominent and promising segment of the overall pharmaceutical industry. Owing to the growing number of start-ups that are engaged in R&D of novel biologics, there is significant opportunity for the CMOs in this domain. It is worth highlighting that, since 2000, more than 115 new

March 28, 2019

The Emergence of Encapsulated Cell Therapies and Affiliated Technologies

By Arun Gupta Cell encapsulation, Cell Therapy 0 Comments

Extensive research on Cell Therapies encapsulation strategies have enabled the development of a variety of technologies capable of confining therapeutic entities within biocompatible matrices / carriers. Since 2013, over 3,000 patents have been published related to the aforementioned type of therapy, indicating the rapid pace of R&D activities in this domain. I have highlighted below

March 14, 2019

Bone Cement Delivery Systems: Current Landscape, Growth Opportunities and Future Market Outlook

By Arun Gupta Delivery Systems, Uncategorized 0 Comments

According to a study conducted by the International Osteoporosis Foundation (IOF), more than 200 million individuals around the world suffer from osteoporosis. In fact, a total of 8.9 million fractures per year are attributed to osteoporosis. The annual socioeconomic burden associated with this condition is estimated to be around USD 19 billion and EUR 37

March 11, 2019

Cybersecurity in Healthcare: The Impending Threat

By Arun Gupta Cybersecurity, Healthcare 0 Comments

Organizations, in the process of collating and storing huge volumes of data on digital platforms, end up placing themselves at enormous risk of losing valuable information to cybercriminals. Estimated annual losses attributed to cyberattacks committed globally, amount to over USD 100 billion. The year 2017 witnessed several cyberattacks; notable examples include WannaCry and NotPetya ransomware

March 7, 2019

Alzheimer’s Disease Market: Pipeline Review, Developer Landscape and Competitive Insights

By Arun Gupta Alzheimer's Disease 0 Comments

It was estimated that, in 2018, nearly 5.7 million Americans (considering all age groups) were living with Alzheimer’s disease. During the same year, Alzheimer’s Disease Market and other dementias were projected to be responsible for a healthcare burden amounting to USD 277 billion, in the US. Despite extensive research aimed at comprehending the etiopathogenesis of

March 1, 2019

Stem Cell Therapies: Upcoming Opportunities in Cardiovascular and Metabolic Disorders (CVMD)

By Arun Gupta Cell Therapy, Stem Cells 0 Comments

Cardiovascular disorders and metabolic disorders are considered to be amongst the leading causes of death worldwide. In fact, approximately one-third of the annual number of deaths across the globe are attributed to cardiovascular disorders. Likewise, a significant proportion of the global population suffers from diabetes or some form of metabolism related clinical condition. As per

February 26, 2019

Patient Recruitment: Market Landscape and Opportunities for Contract Service Providers

By Arun Gupta Contract Service Providers, Patient Recruitment 0 Comments

It is estimated that 80% of clinical trials do not meet their designated patient enrolment deadlines. In addition, retaining patients is also a matter of concern, considering that the approximate dropout rate across clinical studies is around 30%. Delays in product launch, due to inability of the sponsors to recruit / retain patients, are highly

February 20, 2019

Next Generation Contact Lenses and Visual Prosthesis: Rising Popularity to Drive a Multibillion Dollar Market

By Arun Gupta Ophthalmic Lenses, Visual Prosthesis 0 Comments

For more than five decades, contact lenses have primarily been used to correct vision-related disorders. The existence of several unmet needs in the field of ophthalmology, recent technological advances and the availability of new biomaterials, have substantially expanded the range of potential application areas for contact lenses. It is also worth highlighting that Visual Prosthetics,

January 31, 2019

Drug Delivery Technologies: Emerging Paradigms Shaping the Future of Biologics

By Arun Gupta Biologics, Drug Delivery 0 Comments

Given their high target specificity and limited toxicity compared to small molecule drugs, biotherapeutics have revolutionized treatment paradigms across a myriad of clinical conditions, including metabolic disorders, cancers, neurological disorders and autoimmune disorders. In fact, the extent of growth of such therapies can be gauged from the fact that more than 300 biopharmaceuticals have been

January 24, 2019

In Vitro ADME Testing: The Rise of Service Providers

By Arun Gupta ADME Testing, Contract Research Organizations, Drug Discovery 0 Comments

It is important to note that the process of drug discovery is extremely demanding, both in terms of capital and time. In fact, the overall amount spent on R&D initiatives in the pharmaceutical / biotechnology sector has increased from around USD 128 billion in 2008 to USD 165 billion in 2018. Moreover, only a small

December 6, 2018

Large Volume Wearable Injectors: The Goldrush Continues

By Arun Gupta Drug Delivery, Medical Devices and Technology 0 Comments

The self-injection devices market is currently characterized by the presence of a myriad of advanced and innovative drug delivery solutions, equipped with a variety of user-friendly features. Notable examples of such products include prefilled syringes, reusable and disposable pen injectors, autoinjectors and large volume wearable injectors. Large volume wearable injectors are capable of drug delivery

November 15, 2018

Chronic Kidney Disease (CKD) Market: Pipeline Review, Developer Landscape and Competitive Insights

By Arun Gupta Chronic Kidney Disease 0 Comments

It is worth highlighting that over 90% of the patients suffering from reduced kidney function are unaware of their medical condition. In the US, 15% of adults are reported to be suffering from mild or severe forms of CKD. In fact, the mean global prevalence of CKD, across all five stages of the disease, is

November 6, 2018

Genomic Data Management: Opportunities for Blockchain Platform Providers

By Arun Gupta Antibodies, Biologics, Cell Therapies, Contract Research Organizations, Healthcare, LIFESTYLE 0 Comments

It is estimated that, by 2025, around 15% of the world’s population will have had their genomes sequenced, resulting in the generation of several zettabytes of data. However, currently, there are not many reliable and secure data management resources that offer secure storage, seamless exchange of information, and a reliable transaction platform, for large volumes

October 26, 2018

Drug Adherence Enhancement: Novel Approaches to Drive Future Growth

By Arun Gupta Drug Adherence, Medical Devices and Technology 0 Comments

It has been estimated that, of the ~4 billion annual prescriptions filled by the retailers in the US, approximately 50% are not taken by patients in accordance to physicians’ instructions. According to the US Centers for Disease Control and Prevention (CDC), failure to comply to prescribed treatment regimens has been identified as the cause of

October 18, 2018

The Rise of Cell and Gene Therapy CROs

By Arun Gupta Cell Therapies, Contract Research Organizations, Gene Therapy 0 Comments

Over 500 cell and gene therapy candidates are being investigated in different stages of clinical development across various geographies. In fact, in the past five years alone, more than 1,000 clinical trials, that are currently active, were initiated to evaluate the potential of these therapies across multiple therapeutic indications. Due to several development challenges, such

October 5, 2018

Real World Evidence: Unearthing the Gold Mine

By Arun Gupta Contract Research Organizations, Healthcare 0 Comments

Estimates suggest that each prescription drug requires an average of about 10 years and over USD 2.5 billion in working capital before it gets commercialized. In order to gain regulatory approval and establish standards for the safety and efficacy of these products, randomized clinical trials (RCTs) are conducted; these account for a staggering 40% of

October 4, 2018

The Rise of Medical Device CROs

By Arun Gupta Contract Research Organizations, Medical Devices and Technology 0 Comments

According to the World Bank, more than 50,000 different types of Medical Device are currently being used every day in health care facilities worldwide. In 2018, the global medical devices market is estimated to reach a net worth of approximately USD 450 billion. However, a relatively larger proportion of device developers lack the required internal

September 27, 2018

Pre-Sterilized / Ready-to-Use (RTU) Primary Packaging: Current Market Landscape and Future Growth Opportunities

By Arun Gupta Pharmaceutical Packaging, Pharmaceuticals 0 Comments

The use of ready-to-use (RTU), or pre-sterilized / pre-treated, container-closure systems have emerged as a promising alternative to conventional primary packaging, adding significant value to streamline pharmaceutical fill / finish operations. These packaging components eliminate multiple steps in the overall fill / finish process (mainly washing, sterilizing and preparing containers), thereby, helping improve operational efficiencies

September 27, 2018

Cold Chain Logistics for Healthcare: Emerging Opportunities in Cell Therapies, Vaccines and Human Organs

By Arun Gupta Cold Chain, Logistics 0 Comments

Presently, a wide variety of pharmaceutical products, such as biologics, vaccines, human organs for transplantation and certain conventional pharmacological interventions as well, are temperature sensitive and require freezing / cryogenic holding temperatures. In fact, over 95% of all approved biologics and 90% of all vaccines are cold chain dependent. Stakeholders in this segment have designed

September 25, 2018

Extractables and Leachables Testing: Emerging Opportunities for Service Providers

By Arun Gupta Medical Devices and Technology, Pharmaceuticals 0 Comments

During drug product manufacturing and fill / finish, it is important to consider not only the impurity profiles of the drugs, but also identify potential sources of contamination in the containers / packaging material used. due to high variability in the type of impurities (organic (volatile, non-volatile or semi- volatile compounds) or inorganic (metals or

September 11, 2018

ADC Manufacturing: Current Landscape, Growth Opportunities and Future Market Outlook

By Arun Gupta Antibodies, Biologics 0 Comments

Antibody drug conjugates (ADCs) are one of the most popular classes of targeted therapeutic agents and have captured the attention of both large and small pharmaceutical companies, and academic / research institutions across the world. Owing to the fact that these novel conjugates are highly potent toxic molecules, their manufacturing requires elaborate technical capabilities, along

September 4, 2018

Neurostimulation Devices: Competitive Landscape, Market Evolution and Opportunity Areas

By Arun Gupta Medical Devices and Technology 0 Comments

Extensive research in the field of Neurostimulation has demonstrated the potential of this technique in providing therapeutic relief to a number of patients, who have developed resistance to conventional medication. Since the introduction of the first neurostimulation therapy in 1960s, their numerous observed benefits, such as reversible and minimally invasive nature of the procedures (to

August 23, 2018

Antibody Discovery: The Rise of Services and Platform Providers

By Arun Gupta Antibodies, Biologics, Immunotherapy 0 Comments

Owing to several beneficial features, such as high specificity, and a favorable safety profile, antibody Discovery based pharmacological interventions, with 79 molecules approved till date and over 200 molecules in the preclinical / discovery stages, presently represent the largest class of biologics. The discovery of antibodies is a long, arduous and cost intensive process. As

August 2, 2018

Non-Opioids Chronic Pain Management Drugs and Devices: Future Roadmap to USD 10 Billion+ Opportunity

By Arun Gupta Healthcare, Medical Devices and Technology 0 Comments

Owing to the rapid onset of their medicinal effect, which offers immediate relief with high efficacy, opioids are still considered to be one of the most widely used pharmacological interventions for the management of moderate to severe forms of pain. However, these drugs are known to induce a euphoric state upon intake, often causing patients

July 13, 2018

CAR-T: The Future Roadmap of The USD 15 Billion+ Opportunity

By Arun Gupta Biologics, Cell Therapies, Future Perspectives, Immunotherapy, Oncology, Uncategorized 0 Comments

Although cancer therapeutics continue to be one of the most active areas in terms of drug development, there is still a significant unmet need in this domain. Conventional cancer treatments, such as chemotherapy, surgery and radiation therapy, have demonstrated very limited efficacy in late-stage cancers. Amidst the current initiatives to develop more targeted anti-cancer therapies,

July 11, 2018

Cell Therapy Manufacturing: The USD 8 Billion+ Growth Opportunity

By Arun Gupta Cell Therapies, Future Perspectives, Immunotherapy, Therapeutics 0 Comments

Cell Therapy have gained significant attention in the overall biopharmaceutical industry. The personalized nature of these treatment options render them highly specific and, according to a number of clinical studies, safe and efficacious. Around 20 such therapies have been approved so far; recent approvals include Alofisel® (2018), YESCARTA® (2017) and Kymriah® (2017). It is also

July 5, 2018

The Meteoric Rise of Digital Therapeutic, Monitoring and Diagnostic Solutions

By Arun Gupta Diagnostics, Therapeutics 0 Comments

Chronic disorders, such as diabetes, heart disease, obesity, mental health problems and insomnia, are considered to be the leading causes of death and disability across the world. According to a 2018 report published by the Center for Managing Chronic Disease at the University of Michigan, more than 50% of the global population currently lives with

June 27, 2018

Computer Aided Drug Discovery: Opportunities to Optimize the Growing R&D Expenses

By Arun Gupta Drug Discovery, Pharmaceuticals 0 Comments

Given the increase in complexity of the drug discovery process, the overall R&D spending in the pharmaceutical / biotechnology sector has grown from around USD 128 billion in 2008 to USD 158 billion in 2017. As a result, the industry is currently under tremendous pressure not only to meet the expectations of a growing patient

June 13, 2018

Subcutaneous Biologics, Technologies and Drug Delivery Systems

By Arun Gupta Biologics, Drug Delivery 0 Comments

Biologics constitute a majority of the top selling drugs and represent one of the fastest growing segments of the overall pharmaceutical industry. In fact, the share of biologics in the overall pharmaceutical market has increased from 16% in 2006 to over 25% in 2017. Having reported over 70% increase in revenues over the past 5-6

May 23, 2018

Parkinson’s Disease Market: Pipeline Review, Developer Landscape and Competitive Insights

By Arun Gupta Parkinson’s Disease 0 Comments

Parkinson’s disease is known to affect 1-2 per 1,000 individuals and has been shown to impact approximately 1% of the population aged above 60 years. The disease has been estimated to incur combined direct and indirect costs of close to USD 25 billion in the US annually. Despite the availability of several types of dopamine

May 16, 2018

Autoinjectors: Technological Evolution, Current Opportunities and Key Future Growth Areas

By Arun Gupta Autoinjectors, Pharmaceuticals 0 Comments

Since the introduction of the first autoinjector device in 1980s, their numerous benefits, such as ease-of-use, reduced chances of dosing errors, integrated safety mechanisms, and almost negligible risk of needlestick injuries, have been widely recognized among consumers and healthcare service providers. Autoinjectors are also considered to be potential life cycle management tool. Drugs nearing patent

May 15, 2018

New Frontiers in Cancer Therapies: Focus on Transcription Factors, GTPases, Phosphatases and GPCRs, 2018-2030

By Arun Gupta Future Perspectives, Oncology 0 Comments

https://www.rootsanalysis.com/blog/adc-manufacturing-current-landscape-growth-opportunities-and-future-market-outlook/ Cancer Therapies continues to be one of the most active segments within the pharmaceutical industry. However, certain biological targets have long eluded drug development efforts. One such target is Ras family, which has been identified to play a critical role in oncogenesis. Scientific literature suggests that the RAS gene is mutated across about 30%

April 27, 2018

Bioavailability Enhancement: Current Market Landscape and Future Opportunities

By Arun Gupta Pharmaceuticals 0 Comments

Low bioavailability is one of the primary concerns associated with marketed drugs; in fact, various studies indicate that around 40% of available drugs are poorly bioavailable / soluble. As the drug developers shift their focus towards development of lipophilic drug compounds, the issue with aqueous solubility / bioavailability of the drugs is likely to be

April 25, 2018

Next Generation Batteries: Mapping the Future Potential

By Arun Gupta Li-ion batteries 0 Comments

In contrast to the conventional Li-ion batteries, next-generation product chemistries, which include lithium polymer, solid-state, thin film and printed batteries, have been proven to be safe under abusive conditions, demonstrated significant improvements in terms of overall performance, and are environmental-friendly. Moreover, owing to their flexible form factor, it is believed that these batteries can offer

April 19, 2018

Viral Vectors and Plasmid DNA Manufacturing: Current Landscape and Opportunity Areas

By Arun Gupta Biologics, Gene Therapy, Immunotherapy 0 Comments

Over the last few decades, various Viral Vectors and non-viral vectors have been developed, optimized and standardized for introduction of therapeutic DNA / gene of interest into a patient’s body / cells. Currently, the most popular viral vectors, on the basis of their use in active clinical trials, are those based on AAV, adenovirus, lentivirus

April 19, 2018

Pharmaceutical Spray Drying: Current Market Landscape and Future Growth Opportunities

By Arun Gupta Biologics, Pharmaceuticals 0 Comments

Spray drying, which is already established in the food and chemical sector, is also considered to be a rapid, cost-effective, and scalable process for the production of dry powder formulations of pharmacological material. Owing to characteristics, such as reproducibility and its continuous mode of operation, the technique has become very popular in the pharmaceutical and

April 17, 2018

T-Cell Immunotherapies: The Goldrush Continues

By Arun Gupta Biologics, Immunotherapy, Oncology 0 Comments

Amidst the current initiatives to develop more targeted anti-cancer therapies, immunotherapy has emerged as a highly potent option to eradicate tumor cells with minimal side effects. It is based on the principle of harnessing the innate potential of the immune system to target and destroy diseased cells. It encompasses several treatment approaches, such as monoclonal

March 28, 2018

The Growing Importance of Oral Proteins and Peptides

By Arun Gupta Biologics, Healthcare, Oral Delivery, Therapeutics, Uncategorized 0 Comments

Oral Proteins and peptide-based therapeutics have been in use for more than three decades since the approval of recombinant human insulin, the first protein therapy, in 1982. Earlier, most biologic drugs were delivered through the subcutaneous route. However, over time, advances in delivery formulations have enabled the development of orally administrable versions of therapeutic proteins

March 16, 2018

Pharmaceutical Contract Manufacturing: Current Market Landscape and Future Opportunities

By Arun Gupta Healthcare, Pharmaceuticals, Therapeutics, Uncategorized 0 Comments

The present pipeline of pharmaceutical products is becoming increasingly complex and requires specialized facilities, equipment and operational expertise. In addition, the costs associated with acquiring manufacturing capabilities are exorbitant and, therefore, it is difficult for companies with limited finances and capacity constraints to succeed by themselves. Over the years, the contract manufacturing market has grown

February 21, 2018

Gene Therapies: Mapping the Future Growth Potential

By Arun Gupta Future Perspectives, Gene Therapy, Healthcare, Immunotherapy, Oncology, Pharmaceuticals, Therapeutics 1 Comment

The first gene therapy, Gendicine®, was only approved in 2003 in China; since then, the domain has evolved significantly. The ‘Gene Therapy Market (2nd Edition), 2018-2030’ report provides an extensive study on the current market landscape of gene therapies, with a prime focus on gene augmentation based therapies and oncolytic viral therapies, featuring an elaborate discussion on the

February 8, 2018

Smart Grids: Current Market Landscape and Future Opportunities

By Arun Gupta Smart Grids 1 Comment

With growing electricity consumption, the peak electricity demand is expected to increase manifold by 2050. It is believed that, owing to their intelligence features, smart grids have the potential to reduce the projected peak demand increases by up to 24% across some of the major regions of the world. This is because sensors in smart

February 6, 2018

Novel Drugs and Smart Devices for Respiratory Disorders: Mapping the Future Potential

By Arun Gupta Future Perspectives, Healthcare, Therapeutics 0 Comments

The World Health Organization (WHO) estimates the global prevalence of two of the most common chronic respiratory diseases, namely asthma and chronic obstructive pulmonary disease (COPD), to be around 335 million and 400 million patients respectively. According to the data provided by the WHO, more than 3 million people die annually from COPD. Asthma, on

January 11, 2018

Cybersecurity in Healthcare: A Must Have in Today’s Digital World

By Arun Gupta Cybersecurity, Future Perspectives, Healthcare 1 Comment

The healthcare industry has been amongst the prime targets for hackers over the last several years. In 2017, the healthcare industry had been compromised a number of times, representing 25% of the total number of breaches worldwide. Across these instances, around 31 million records were compromised, stolen or lost. In order to overcome these challenges,

December 15, 2017

Back of the Eye Disorders: The Emergence of Novel Drugs and Delivery Technologies

By Arun Gupta Future Perspectives, Medical Devices and Technology, Pharmaceuticals 0 Comments

The current treatment landscape for back of the eye disorders is characterized by the presence of blockbuster Novel Drugs, such as Lucentis® and Eylea®, and various other therapeutic options. Despite the success of these therapies, their invasive mode of administration, high dosage frequency and other drug related side effects, are some of the drawbacks that

December 6, 2017

Cancer Stem Cell Therapies: Mapping the Future Growth Potential

By Arun Gupta Cell Therapies, Pharmaceuticals 0 Comments

The objective of the ongoing R&D in this domain is to develop novel CSC directed treatments that can combat complications, such as off-target toxicities and disease relapse, associated with the current standard of care treatments. The ‘Cancer Stem Cell Therapies Market, 2017-2030’ report examines the current landscape and the future outlook of the growing pipeline of products

November 20, 2017

3D Bioprinting: What Lies Ahead?

By Arun Gupta 3D Bioprinting 0 Comments

The current applications of 3D bioprinted products cater to various requirements within the pharmaceutical industry for clinical testing of therapeutic drugs. The ‘3D Bioprinting: Technologies, Products and Key Application Areas, (2nd Edition), 2018-2035’ report provides a comprehensive study on the current market landscape of the 3D bioprinting industry, featuring an elaborate discussion on the future potential of this evolving market. Some of

November 17, 2017

Non-Antibody Protein Scaffolds: A Niche but Highly Promising Opportunity Area

By Arun Gupta Non-Antibod 0 Comments

Amongst other novel formats, non-antibody protein scaffolds have emerged as viable alternatives to conventional therapies, having the capability to address the existing challenges associated with classical antibody based therapies. The ‘Non-Antibody Protein Scaffolds: Drugs and Diagnostics Market, 2017-2030’ report provides a comprehensive study of the current market landscape of non-antibody protein scaffolds, and related drugs and diagnostics, featuring an

October 26, 2017

Antibody Drug Conjugates: Riding on the Second Growth Wave

By Arun Gupta Oncology, Pharmaceuticals, Therapeutics 0 Comments

While there are close to 200 ADCs in various stages of development, the market field is currently going through a gradual transition, shifting from relying on conventional technologies to newer approaches for generating ADCs. The ‘Antibody Drug Conjugates Market (4th Edition), 2017-2030’ report provides a comprehensive study on the current landscape of ADCs, featuring an elaborate discussion

October 25, 2017

Biopharmaceutical Contract Manufacturing: Transforming Promise into Reality

By Arun Gupta Biopharmaceutical 0 Comments

Antibody Drug Conjugates: Riding on the Second Growth Wave

The development and manufacturing processes for biologics are complex, and usually require advanced capabilities and specialized expertise. This has led many stakeholders in the biopharmaceutical industry to outsource significant parts of their business operations to contract service providers. The ‘Biopharmaceutical Contract Manufacturing Market (2nd edition), 2017 – 2027’ report provides an extensive study of the contract manufacturing

October 20, 2017

Cell Line Characterization: Current Landscape and Future Market Evolution

By Arun Gupta Cell Line, Diagnostics, Future Perspectives 0 Comments

Cross contamination and cell line misidentification are some of the major concerns associated with the use of cell lines. It has been estimated that a net loss of USD 28 billion is incurred every year on research that cannot be replicated due to the involvement of misidentified or contaminated cell lines in the US. To

October 18, 2017

Antibody Discovery: The Rise of Services and Platform Providers

By Arun Gupta Antibody Discovery 0 Comments

The rising demand for personalized medicines to provide targeted treatment options has encouraged pharmaceutical companies to shift their focus from small molecules to discovery and development of biologics, particularly antibody-based therapeutics. The ‘Antibody Discovery: Services and Platforms, 2017-2027’ report provides an extensive study on the current market landscape and future outlook of the antibody discovery service and

October 6, 2017

Modular Facilities in Pharma / Biotech: An Evolutionary Leap Forward

By Arun Gupta Biotech 0 Comments

Modular facilities have demonstrated tremendous potential in several fields; specifically, the shorter time taken to establish such facilities has a significant impact on expediting various operational processes. The ‘Modular Facilities in the Pharma / Biotechnology Industry, 2017-2030’ report provides an extensive study on the current market landscape and future outlook of modular facility manufacturers that

September 28, 2017

3D Cell Cultures: A Multi-Billion Dollar Growth Opportunity

By Arun Gupta 3D Cell 0 Comments

The use of advanced 3D cell culture techniques in in vitro studies is seen to have the capability to overcome several challenges associated with 2D systems. The ‘3D Cell Cultures: Products, Technologies and Key Application Areas (2nd Edition), 2017-2030’ report features an extensive study on the various scaffold-based and scaffold-free 3D culture systems. Some of

September 27, 2017

Bispecific Antibodies: Current Landscape, Market Trends and Future Outlook

By Arun Gupta Antibodies 0 Comments

Bispecific antibodies have demonstrated the capability to address the existing challenges associated with monoclonal antibodies, such as high manufacturing costs, limited applicability in assays and the general lack of understanding of precise in vivo mechanisms of action. The ‘Bispecific Antibody Therapeutics Market (3rd Edition), 2017-2030’ report provides a comprehensive study of the current landscape of bispecific antibodies, featuring an

August 31, 2017

Deep Learning: Opportunities in Drug Discovery and Diagnostics

By Arun Gupta Drug Discovery 0 Comments

Deep learning is a novel machine learning technique that can be used to generate relevant insights from large volumes of data. The applications of the technology are being explored across a variety of areas. The ‘Deep Learning: Drug Discovery and Diagnostics Market, 2017-2035′ report examines the current landscape and future outlook of the growing market of deep learning

August 31, 2017

Liquid Biopsy: Will It Be The Future Gold Standard?

By Arun Gupta Liquid Biopsy 0 Comments

Invasive cancer diagnostic methods, such as tissue biopsies, have been the gold standard to determine the clinicopathological characteristics of cancer tissues for many years. The procedure is not only cost-intensive but is also a traumatic experience for the patients. The ‘Non-Invasive Cancer Diagnostics Market (2nd Edition), 2017-2030’ report provides an extensive study on liquid biopsy kits / assays

August 31, 2017

Cell Therapy Manufacturing: A Niche but Rapidly Growing Multi-Billion Dollar Industry

By Arun Gupta Cell Therapy 0 Comments

Post the approval of first cell-based therapy, Carticel®, in 1997 in the US, the field has rapidly advanced and a number of such therapies are currently under development. The ‘Cell Therapy Manufacturing Market, 2017-2027’ report provides an extensive study of the rapidly growing market of cell therapy manufacturing and focuses both on contract manufacturers and cell therapy

August 31, 2017

Large Volume Wearable Injectors: The Goldrush Continues

By Arun Gupta Injectors 0 Comments

The large scale adoption of prefilled syringes demonstrated the growing interest in the concept of such convenient drug delivery systems. Large volume wearable injectors are advanced versions of the existing self-injection devices. The ‘Large Volume Wearable Injectors Market (3rd Edition), 2017-2027′ report features an extensive study of the current landscape and the likely future evolution of this category

August 24, 2017

Antibody Humanization and Affinity Maturation: Current Market Landscape and Opportunity Areas

By Arun Gupta Antibody Humanization 0 Comments

Certain steps of antibody drug discovery require advanced expertise, and companies offering these specialized services have attracted significant attention of drug / therapy developers. Two such specific services are to reduce antibody immunogenicity (humanization) and enhance its affinity (affinity maturation). The ‘Antibody Humanization and Affinity Maturation: Services and Platforms, 2017-2030’ report provides a comprehensive view on the current landscape and the

August 3, 2017

Cell Line Development: A Gold Mine for Service Providers

By Arun Gupta Cell Line, Pharmaceuticals 0 Comments

Owing to their use in the manufacturing of biologics and biosimilars, and various application areas, such as drug screening, gene functional studies, cell-based assay development, diagnostics and tissue engineering, there is growing demand for different types of cell lines. The ‘Cell Line Development Services Market, 2017 – 2027’ report provides an extensive study of the rapidly growing market

August 3, 2017

Microbiome Therapeutics and Diagnostics: Unlocking the Future Potential

By Arun Gupta Diagnostics, Future Perspectives, Microbiology, Therapeutics 0 Comments

Microbiome therapeutics represent a new frontier in the field of medicine. Currently, there are many probiotics, prebiotics, and medical foods and supplements that are commercially available, and several drug / therapy candidates that claim to be capable of modifying / manipulating the microbiome in order to provide therapeutic benefits. The ‘Microbiome Therapeutics and Diagnostics Market (2nd Edition), 2017-2030’ report provides a